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Chapter 1: Aim of the work 
 
Parenteral and oral administration of lipophilic drugs is often problematic because of 
their intrinsic low water solubility. Among other colloidal drug delivery systems, lipid 
nanoparticle carrier systems are of interest for intravenous drug delivery. These drug delivery 
systems are often derived from physiological structures and have compositions similar to 
their physiological counterparts; therefore, physiological acceptance is expected for many of 
these types of carriers. Physiological lipids are expected to be metabolized rapidly, resulting 
exclusively in non-toxic breakdown products. Due to the production by high-pressure 
homogenization lipid nanoparticles can be produced on large industrial scale. These 
advantages make lipid nanoparticles as one of the most interesting colloidal carrier systems. 
In order to rationally design colloidal carrier drug delivery systems and to obtain information 
on their potential in-vivo performance, it is necessary to fully characterize their drug retention 
and release properties. For that purpose, a simple and effective in-vitro assay is required. 
Several methods have been used to measure the drug release from colloidal carrier systems. 
Many common release methods appear to be of limited suitability to draw conclusions to the 
in-vivo performance of colloidal carriers. This is due to the binding of some drug to the filter 
material and the use of aqueous release media like ordinary buffer solutions. Also 
methodological problems like the blockage of the applied filter by the colloidal particles can 
be a problem. In order to approach in-vivo conditions, the buffered media are sometimes 
supplemented for example with albumin [1-2]. Nevertheless, these conditions are not 
representative for the situation in the bloodstream, which would, however, be highly 
desirable. Furthermore, the low aqueous solubility of many of the drugs of interest 
complicates their analysis in aqueous media.  
The aim of this study was focused on overcoming these problems and finding more 
realistic release conditions with special attention to intravenous administration. To approach 
this, the transfer from lipid nanoparticles into lipophilic acceptor compartments was 
measured by different techniques. The lipophilic acceptor compartments are intended to 
mimic lipophilic compounds present in the blood, e.g. lipoproteins or cellular structures and 
thereby present a compartment in which the released lipophilic substance is soluble. 
Determination of the factors, which affect the drug transfer from the lipid nanoparticles into 
the different lipophilic acceptors, was an important goal of the study. Another important aim 
of the study was the comparison between the different techniques, which were used to 
measure the transfer from lipid nanoparticles into lipophilic acceptor compartments, to find 
the most suitable one for evaluating the drug release behaviour of such lipid nanoparticles 
and to determine the limitations of each technique. 
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Three techniques were employed to study the drug transfer from lipid nanoparticle 
carrier systems to lipophilic acceptor particles with different particle sizes and compositions. 
Factors affecting the drug transfer from these carrier systems, such as composition and 
particle size of the acceptor particles as well as drug lipophilicity were studied using these 
techniques.  
The first technique was based on the use of ion exchange columns which was 
described in detail by Fahr and co-workers [3]. The transfer kinetics of three drug models 
with different degrees of lipophilicity, porphyrin, Nile red and Di  was investigated in this 
study. Under the selected conditions, these three drug models are transferred from 
negatively charged donor lipid nanoparticles to different lipophilic neutral acceptor 
nanoparticles. Three different lipophilic acceptor particles were used. The first type of 
acceptor consisted of unilamellar vesicles [4], the second one of a Miglyol nanoemulsion and 
the third type of acceptor particles were monoolein dispersions in the form of vesicles or 
cubic particles. This technique depends on the use of charged donor particles, which can be 
retained by the ion exchange column.  
The second technique was based on centrifugation where the transfer kinetics of the 
same three drug models were investigated. The transfer of these drug models was measured 
from various lipid nanoparticles to three different lipophilic acceptors, multilamellar vesicles 
(MLV), o/w emulsion and cubic particles. Separation of both populations (donor and 
acceptor) was done by centrifugation. This technique using MLV was first presented by 
Shabbits and co-workers [5]. 
The third technique used flow cytometry to detect the drug transferred into the acceptor 
particles. The transfer kinetics from different donor lipid nanoparticle carrier systems into 
lipophilic acceptor compartments was measured. Three different types of acceptor 
compartments in the micrometer size range were compared using this technique, MLV, o/w 
emulsion and monoolein cubic particles. Only the large acceptor particles can be detected by 
the flow cytometer (not the small donor nanoparticles) thus no critical separation step has to 
be included and the transfer mixture can be analyzed in situ after dilution.  The use of flow 
cytometry to measure drug transfer process was described recently [6]. 
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2.1 Colloidal drug carrier systems 
In recent years it has been noticed that the development of new drugs alone is not 
enough to ensure progress in drug therapy due to the therapeutic failure that was observed 
with these new drugs. To overcome this problem, it was important to develop suitable drug 
delivery systems or drug carrier systems [7]. Drug delivery systems have an important role in 
pharmaceutical sciences because they affect drug transport, absorption, distribution and 
elimination. These drug delivery systems should show many characteristics to be accepted 
as beneficial carrier systems. One of the most important characteristics of these systems is 
to deliver difficult drugs such as lipophiles to the site of action (drug targeting) with a 
controlled release manner. Other properties such as ease of production, ease of 
administration and the physiological safety are also required with the different systems [7]. 
Lipophiles are poorly water-soluble molecules, which have a lot of important roles in 
different biological processes. Many drugs are lipophilic such as anticancer drugs [8], 
antifungal agents [9] and antioxidants [10-11]. Most scientists prefer parenteral delivery for 
the targeting of lipophilic drugs [12] but this requires the use of small particle sizes because 
the smallest capillary is approximately 5 µm in diameter so parenteral delivery systems must 
be colloidal in nature.  
O/w emulsions were the first commercial colloidal delivery carriers of lipophilic drugs. 
This colloidal carrier exhibits several disadvantages, which are related to the oil and to the 
properties of the emulsion as a carrier system [7, 13]. Oils that can be used medically show 
low solubility for most drugs. In addition to this problem emulsions exhibit drug burst release 
phenomena due to their liquid state. Due to these limitations or disadvantages, it was 
important to develop other colloidal carrier systems to overcome the disadvantages that were 
encountered with the emulsion system. Colloidal carriers such as liposomes, cubic particles 
and lipid nanoparticles have attracted increasing attention during recent years [7, 13].  
 
2.1.1 Liposomes 
 Liposomes are spherical vesicles, which consist of one or more phospholipid bilayers. 
Lipophilic drugs can be entrapped in the vesicle bilayer or partition between the bilayer and 
the aqueous phase while hydrophilic drugs are entrapped in the inner aqueous core [14]. A 
wide variation of lipids can be used to prepare vesicles. Phospholipids, which are the main 
component of biological membranes, have a high tendency to aggregate and to form 
vesicles. Phosphatidylcholine (PC) has been used as the major component for the 
preparation of liposomes [14]. The properties of liposomes such as rigidity and permeability 
of the bilayer depend on the type and quality of PC and other bilayer lipids used. Cholesterol 
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is highly used in the preparation of liposomes and increases the rigidity of the bilayer. Due to 
the molecular shape and solubility properties of cholesterol, it fills in empty spaces among 
the phospholipid molecules, thereby increasing the strength of the bilayer. Liposomes are 
classified as large multilamellar vesicles (MLV, > 0.5 µm), large unilamellar vesicles (LUV, > 
100 nm), small unilamellar vesicles (SUV, 20-100 nm), oligolamellar vesicles (OLV, 0.1-1 
µm) and multivesicular vesicles (MVV, > 1 µm). This classification depends on size, the 
number of bilayers and the existence of inner vesicles in a vesicle [14-15]. 
 Liposomes as drug carriers can be used for the intravenous administration of different 
lipophilic drugs. Liposomes show a high physiological acceptance due to the use of biological 
phospholipids in their preparation. Liposomes have been used as model membranes and as 
carriers of drugs, DNA and enzymes. Despite of their high physiological safety, there are 
many disadvantages of using liposomes as colloidal carriers such as the chemical and 
physical stability problems which may cause their aggregation during storage [14]. In addition 
to these chemical and physical problems the production costs of liposomes are very high in 
comparison with other colloidal systems.  
 
2.1.2 Cubic particles 
Another important colloidal drug delivery system is particles with cubic internal 
structure. Monoolein water mixtures form different lyotropic liquid crystalline structures in 
dependence on concentration and temperature [16]. In the presence of excess water, a 
bicontinuous cubic phase is formed at room and body temperature. It consists of a pair of 
interpenetrating but non-contacting water channels separated by a single, highly curved 
continuous lipid bilayer. This bilayer structure extends in three dimensions with a high 
specific bilayer/water interfacial area [17] as illustrated in figure 2.1 [18-19]. Due to its unique 
structure the cubic phase can host lipophilic as well as amphiphilic and hydrophilic 
substances and has thus often been used to incorporate and slowly release different types of 
drugs, e.g acyclovir and somatostatin [20-21]. Furthermore, the cubic phase was used for 
determining the lipid bilayer/water partition coefficient of drug compounds [17]. In addition to 
the above studies, colloidal dispersions of cubic particles named cubosomes [22-23] were 
used to study the release of somatostatin, insulin and cyclosporin [24]. As the bicontinuous 
cubic phase is stable in excess water, dispersions of cubic particles (often called 
“cubosomes”) can be prepared.  They are typically made by applying high shear (e.g., using 
high pressure homogenization or sonication) to disrupt a coarse dispersion of the very 
viscous cubic phase into small, often submicron-sized particles in the presence of surfactants 
like poloxamer [16, 25]. However, high pressure homogenization and sonication result not 
only in the desirable size reduction of cubic phase particles but also in the formation of 
vesicles. Heat treatment of the homogenized dispersions results in improved properties of 
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cubic phase dispersions such as more uniform size distributions due to the transformation of 
vesicles into cubic particles.  
 
 
 
 
 
 
  
Figure 2.1: Schematic representation of the bicontinuous cubic phase illustrating the non-contacting 
water channels separated by a continuous lipid bilayer (adapted from [18-19]). 
 
2.1.3 Lipid nanoparticles 
The first lipid nanoparticles used in the pharmaceutical field were the lipid 
nanoemulsions, which were used for parenteral nutrition. These lipid nanoemulsions are 
usually composed of about 10-20% fatty vegetable oils or medium chain triglycerides as the 
lipid phase and usually are stabilized with phospholipids. In addition to the use of lipid 
nanoemulsions for parenteral nutrition, it has been observed that these lipid nanoparticles 
might also be used as carrier vehicles for many lipophilic drugs [26-31]. Toxicological safety 
and the possibility of large-scale production by high-pressure homogenization [32-34] are 
advantages of lipid nanoparticles. The toxicological safety of these nanoparticles was related 
to the use of lipids, which have a high physiological acceptance [35-36]. A major drawback of 
the lipid nanoemulsions is the difficulty to obtain controlled drug release due to the small size 
and the liquid state of the carrier. For most drugs, a rapid release of the drug will be 
observed [2, 37-38]. To overcome this major problem, solid lipids instead of liquid oils were 
used to obtain controlled drug release, because drug movement in a solid lipid should be 
less than in liquid oil. The same advantages of the lipid nanoemulsion were also observed 
with the solid lipid nanoparticles in addition to the controlled release, which was expected 
from the solid state of the lipid [39-40]. The controlled drug release expected with the solid 
lipid nanoparticles is due to the solid nature of the lipid and to keep this important advantage 
upon administration the melting point of the lipid must exceed body temperature [7]. Lipids of 
different melting point were employed in the preparation of solid lipid nanoparticles such as 
triglycerides, fatty acids and waxes. Different surfactants were used, especially 
phospholipids, which were often used in this field but it was reported that the use of 
phospholipids as the only surfactant is accompanied by instability and gel formation after 
solidification of the lipid [39, 41]. To overcome this problem a co-emulsifier (ionic co-
emulsifier, e.g. glycocholate or non-ionic surfactant, e.g. tyloxapol) should be used. 
Westesen and co-workers observed the presence of spherical small particles in the solid lipid 
Lipid bilayer 
Water channels 
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nanoparticles stabilized with excess phospholipids. These spherical small particles were 
identified as small unilamellar vesicles from the excess phospholipid emulsifier used [39]. 
 
2.1.3.1 Preparation of lipid nanoparticles  
Many methods were used for the preparation of lipid nanoparticles. Most of these 
methods rely on two steps for the preparation of lipid nanoparticles. The first step is the 
preparation of an o/w nanoemulsion, which is the precursor of the solid lipid nanoparticles 
[7]. The second step is the solidification of the dispersed lipid phase. In order to prepare solid 
lipid nanoparticles in the nanometer size range, which is the suitable size for parenteral 
administration, with an acceptable size distribution of the particles (polydispersity), it is 
important to subject the precursor emulsions to high mechanical forces such as, high 
pressure homogenization (HPH). Two types of HPH were developed [7]. The first type is the 
hot HPH, which works at a temperature above the lipid melting point. After the high 
temperature homogenization, the nanoemulsion must be cooled to a certain temperature to 
ensure the solidification of the lipid nanoemulsion droplets. This temperature of solidification 
of the lipid nanoemulsion droplets differs from the recrystallization temperature of the bulk 
lipid material due to the colloidal size of the lipid nanoemulsion droplets [36, 42] and should 
therefore be determined carefully. Major drawbacks of the hot HPH are the degradation of 
thermo labile drugs and the partitioning of the drug into the aqueous phase, which may be 
related to the increase of drug hydrophilicity with increasing temperature. To avoid these 
drawbacks of the hot HPH, the second type of HPH, which is the cold HPH technique, was 
developed. This technique generally produces larger particle sizes and broader particle size 
distributions. It was reported that high homogenization temperatures produce smaller particle 
sizes due to the decreased dispersed phase viscosity [43]. Although cold HPH avoids the 
partitioning of the drug into the aqueous phase, the stability problems and drug degradation 
were still present due to the high mechanical forces applied during the preparation of the 
nanoparticles. Another drawback of both types of the HPH is the reduction of the molecular 
weights of polymers and the degradation of DNA and albumin [43]. 
 
2.2 Drug release from colloidal carrier systems 
In order to assess colloidal carrier systems such as lipid nanoparticles, it is necessary 
to fully characterize their drug retention and release properties. For this purpose, it is 
important to find a simple and effective in-vitro assay to evaluate the drug release behaviour 
of such particles and to obtain information on their potential in-vivo performance. Many 
methods have been described to investigate the in vitro drug release of colloidal drug 
delivery systems. 
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2.2.1 Sample and separate method 
This method depends on the filtration or centrifugation to separate the particles from 
the release media at different time points followed by drug determination in the release 
medium [2, 44-47]. Common problems that were observed with this method are the blockage 
of the filters by the colloidal particles, binding of drugs to the filter material and instabilities of 
the investigated colloidal systems due to the application of energy during the filtration or 
centrifugation step [48]. In addition, the high centrifugal force, which is required to separate 
the small colloidal particles (less than 300 nm) from the release media, will often lead to an 
increase in the drug release rate [49]. 
 
2.2.2 Dialysis based assay 
This method is one of the most commonly used methods and it depends on dialyzing 
the colloidal particles against large volumes of buffer. The excess buffer serves as a sink as 
an approach to mimic the conditions in the blood and this sink condition increases the drug 
release from the colloidal particles. After drug release from the colloidal carrier, free drug 
crosses the dialysis membrane and accumulates in the buffer system. In some cases the 
dialysis buffer systems were supplied with serum to more closely mimic the physiological 
environment, which the colloidal carriers encounter in-vivo. Different factors can affect this 
dialysis assay such as the size of the membrane surface area as well as the presence or 
absence of different additives in the dialysis buffer medium [50-52]. The main disadvantage 
of this assay is the absence of a real sink condition since the encapsulated drug will be in 
equilibrium with the drug in the continuous phase thus the partition coefficient not the release 
rate is often measured [52-53]. In spite of this disadvantage the dialysis assay has been 
reported to be successfully used for studying the shelf life of liposomes and drug systems 
with respect to drug retention [54].   
 
2.2.3 Continuous-flow method 
This method depends on the continuous circulation of the colloidal carrier particles with 
the release buffer medium in special cells. At one end of the cell samples of the release 
medium are taken and filtered to obtain the free drug while at the other end fresh release 
buffer medium is introduced into the cell to keep the volume of the buffer constant all over 
the experiment. The same disadvantages as for the previous two methods are also observed 
with this method such as the blockage of the filter, which alters the flow rate of the buffer and 
slows the release medium replacement and thus modifies the release kinetics [48, 52, 55]. 
All these three methods encounter the same problem because the conditions of measuring 
the drug release are unlike the conditions in the bloodstream, which would be highly 
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desirable. Another problem is the insolubility of many interesting lipophilic drugs in the 
aqueous release medium employed. To overcome the problems encountered with the 
common methods of measuring the drug release from colloidal carrier systems, other in vitro 
methods were developed. These methods depend on measuring the drug transfer from the 
colloidal carrier systems into lipophilic acceptor particles instead of measuring the drug 
release into an aqueous phase. Some of the most important in vitro methods are 
summarized in the following paragraphs. 
 
2.2.4 MLV based assay 
The MLV method is an in vitro assay which measures the transfer of lipophilic drug 
molecules from colloidal carrier systems as donor particles to multilamellar vesicles (MLVs) 
containing 300 mM sucrose, which serve as acceptor particles and are added in excess with 
regard to the donor nanoparticles. Egg phosphatidyl choline (EPC) and cholesterol were 
chosen for MLV formulation, since they represent an unsaturated and uncharged bilayer that 
is similar to many physiological membranes [5]. Following incubation at 37°C, the two particle 
populations (donor and acceptor) are separated by centrifugation [5]. The amount of drug in 
the MLV pellet reflects the degree of drug release from the donor to the acceptor liposomes. 
The MLV-based drug release assay showed a better prediction of in vivo drug transfer than 
the dialysis based assay [5]. A schematic illustration of this method is given in figure 2.2.  
 
2.2.5 Ion-exchange column based assay 
The ion-exchange mini-column model is an in vitro system for measuring the transfer of 
lipophilic drug molecules from colloidal carrier systems to different liposomal formulations, 
which mimic the membrane binding sites in the body. This assay depends on the use of a 
negatively or positively charged donor colloidal carrier system. Neutral liposomes (mostly 
PC-liposomes) are used as acceptor medium at excess in relation to the donor particles to 
measure the drug release from these donor colloidal carrier systems [56]. After mixing the 
two populations (donor and acceptor), samples are taken at different time points and passed 
over an ion exchange column, which allows only the neutral (acceptor) liposomes to be 
eluted. This model was first presented by Hellings and co-workers [57] and was afterwards 
modified by van den Besselar and co-workers [58]. The principle of the method is illustrated 
in figure 2.3. 
 
2.2.6 Flow cytometry assay 
In this method, the transfer of fluorescent model substances from lipid nanoparticles 
into lipophilic acceptor compartments is studied using flow cytometry [6]. The acceptor 
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droplets are intended to mimic lipophilic compounds as present in the blood. This assay 
relies on the use of large acceptor particles (> 1 µm) in order to enable the detection of the 
acceptor particles by flow cytometry [59-61]. O/w emulsion droplets with particle sizes in the 
micrometer size range were used as acceptor particles to measure the drug transfer from 
different lipid nanoparticles [6]. The important advantage obtained by this method is the good 
time resolution, which is often a problem with other techniques [6]. Since only the large 
acceptor particles are detected by the flow cytometer without significant interference of the 
small donor lipid nanoparticles, no critical separation step between the donor and acceptor is 
required and the transfer mixture can be analyzed in situ after dilution. Thus the flow 
cytometry assay is suitable for the investigation of very rapid drug transfer processes [6]. A 
drawback of the flow cytometric method is the need for fluorescent substances that can be 
detected. Moreover, the size of the acceptor particles should be in the µm-range whereas the 
donor particles size need to be smaller than 500 nm to avoid an interference with the 
acceptor particles in terms of detection.  
Figure 2.2: Schematic illustration of the centrifugation based in vitro drug release assay procedure 
using MLV as acceptor particles. 
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Figure 2.3: Schematic illustration of the in vitro ion exchange column based assay. 
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3.1 Materials 
Table 3.1 shows the different materials, which were used in the experiments, and their 
suppliers. 
  
Table 3.1: Materials used in the experiments and their suppliers 
Substance name Suppliers 
Triglycerides trimyristin (D114, Dynasan 114), 
tristearin (D118, Dynasan 114) and Miglyol 812 
Condea Chemie (D-Witten) 
Monoolein (GMOrphic-801) Eastman Chemical Company (Kingsport, TN) 
Poloxamer 188 (F68, Lutrol F68) and poloxamer 
407 (Lutrol F127) 
BASF AG (D-Ludwigshafen) 
Polyvinyl alcohol, sodium glycocholate (SGC), 
cholesterol, Trizma 7.4 pre-set crystals, sucrose, 
5,10,15,20-tetrakis (4-hydroxyphenyl)-21H, 23H-
porphine, and 1,1-dioctadecyl- 3,3,3,3-
tetramethylindocarbocyanine perchlorate (Di ) 
Sigma-Aldrich (D-Steinheim) 
Partially hydrolyzed poly (vinyl alcohol) (PVA; 
Mowiol 3-83) 
Clariant (D- Frankfurt/Main) 
Diethylaminoethyl (DEAE) Sepharose CL-6B Amersham Biosciences AB (S-Uppsala) 
Egg phosphatidyl choline (EPC), Lipoid S75 and 
Lipoid S75-3 
Lipoid GmbH (D- Ludwigshafen) 
Nile red Acros Organics 
Glycerol Solvay GmbH (D-Rheinberg) 
Thiomersal Caesar and Loretz (D-Hilden) 
Methanol, tris and scintillation cocktail Carl Roth GmbH (D-Karlsruhe) 
Acetonitrile, ethanol and chloroform VWR International (D-Darmstadt) 
Tetrahydrofurane (THF) Fisher Scientific (D-Nidderau) 
Hepes and sodium chloride AppliChem GmbH (D-Darmstadt) 
sodium azide Sigma-Aldrich (D-Seelze) 
Praseodym ( )-chloride (PrCl3) Sigma-Aldrich GmbH (D-Schnelldorf) 
Purified water was prepared by filtration and 
deionization/reverse osmosis 
Milli-Q, Millipore (Billerica, MA, USA) 
3
H-cholesteryl oleyl ether 
GE Healthcare (Amersham, radiochemical, 
Buckinghamshire, UK) 
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3.1.1 Drug models used in the experiments: 
Three fluorescent substances, which have different degrees of lipophilicity, were used as 
drug models in the transfer experiments. These fluorescent drug models were chosen to fit 
with the flow cytometric transfer experiment, which requires the use of fluorescent 
substances. 
Porphyrin: 
Porphyrins are heterocyclic macrocycles derived from four pyrrole-like subunits. A major area 
where porphyrins are showing significant potential is in the treatment of a wide range of 
diseases, including cancer, using photodynamic therapy [62]. The model porphyrin that was 
used in the transfer experiments is 5,10,15,20-tetrakis (4-hydroxyphenyl)-21H, 23H-porphine 
(porphyrin) (figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nile red: 
Nile red (figure 3.2) is fluorescent dye, which is more hydrophilic than porphyrin, it has a logP 
value of about 3.65 [6]. Nile red stains intracellular lipid droplets red and is characterized by a 
strong yellow-gold emission when in a lipid-rich environment [63]. It excites at 485 nm and 
emits at 525 nm.  
 
 
 
 
 
 
 
Figure 3.1: 5,10,15,20-tetrakis (4-hydroxyphenyl)-21H, 23H-porphine (porphyrin) 
Figure 3.2: Molecular structure of Nile red 
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Di : 
Di C18(3) (figure 3.3) is a very lipophilic dye, which is employed to analyze membrane 
structures. Its high lipophilicity was attributed to its two long alkyl chains, which lead to a very 
high logP value (about 20) [64].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Preparation of the donor particles 
 
3.2.1 Preparation of the trimyristin (D114) nanoparticles 
The donor solid lipid nanoparticles (SLN) were prepared by the hot homogenization 
technique. Four formulations of lipid nanoparticles from trimyristin (D114, 5% w/w) were 
prepared as described before [65]. The matrix lipid and the aqueous phase containing the 
surfactant as described in table 3.2 were heated to 70 °C. After melting of the triglyceride, the 
aqueous phase was poured to the molten lipid and the mixture was pre-homogenized for one 
minute (Ultra-Turrax T8, IKA Labortechnic, Germany). This crude emulsion was transferred 
to the 70 °C warm high-pressure homogenizer Microfluidizer M-110S (Microfluidics, US-
Newton) and treated for 5 min at 500 bar except for the FS75 formulation, which was 
homogenized at 600 bar. The dispersions were either stored at room temperature, thereby 
retaining the liquid state of the trimyristin droplets or the droplets were crystallized into 
platelet-like particles by storage of the dispersion at refrigerator temperature (2-8 °C) [36]. To 
separate the solid trimyristin nanoparticles from the excess emulsifier S75, 5 ml samples of 
the nanosuspensions of FS75/SGClow, FS75/SGChigh and FS75 were subjected to 
ultracentrifugation (XL-80 ultracentrifuge, rotor type SW55 Ti, Beckman Coulter Inc., US-
Fullerton) for 1 hour at 35000 rpm and 15°C. 
 
Figure 3.3: Structure of Di  (Di C18(3) 1,1-dioctadecyl- 3,3,3,3 
tetramethylindocarbocyanine perchlorate). 
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Table 3.2: Concentration of the different emulsifiers used in the preparation of the four lipid 
nanoparticle formulations containing 5% trimyristin in an aqueous phase containing 2.25% glycerol 
and 0.01% thiomersal 
 
After removing the aqueous supernatant containing the excess emulsifiers the pellet was 
scraped from the tube bottom, resuspended in 5 ml of aqueous phase and sonicated for  
10 minutes at 60°C (followed by filtration through a 0.45 µm membrane filter for 
FS75/SGClow). The resuspended nanoparticles were stored at room or refrigerator 
temperature. Loading of porphyrin (0.5 mg/ml) was carried out to the original nanoemulsion 
(before cooling and crystallization). A stock solution from porphyrin was prepared in 
methanol (10 mg/ml) and from this stock solution 500 µl was added to 10 ml of the 
nanoemulsion. Shaking of the samples was done for 2 days at 25°C in a shaking water bath 
followed by solidification and ultracentrifugation. Loading of Nile red (0.15 mg/ml) was carried 
out by evaporation of an ethanolic dye stock solution (0.75 mg/ml) in a glass vial leaving 
behind a thin film of Nile red followed by addition of 5 ml of the nanoemulsion FS75/SGChigh 
and shaking at 25°C for 2 days followed by solidification. Di  (0.15 mg/ml) was added to the 
nanoemulsion FS75/SGChigh. A stock solution of Di  was prepared in ethanol (3 mg/ml).  
500 µl from this stock solution was added to 10 ml of the nanoemulsion. Shaking of the 
samples was done for 3 days at 25°C followed by solidification. Small fractions of these 
nanoparticles were stored at room temperature and the remaining fractions were stored at 
refrigerator temperature. 
 
3.2.2 Preparation of the tristearin (D118) nanoparticles 
Two formulations from 5% D118 and different stabilizers were prepared by hot 
homogenization. The first one was prepared with 1.8% Lipoid S75-3 and 0.45% sodium 
glycocholate (SGC) while the second one contained 4% Mowiol 3-83. For the nanoparticles 
stabilized with phospholipid S75-3, the phospholipid and SGC were dispersed/dissolved in 
the aqueous phase (containing 2.25% glycerol and 0.01% thiomersal) by magnetic stirring 
over night. The stabilizer mixture was transiently heated to about 60°C to facilitate 
dispersion. 
Formulation Percentage of the emulsifier Preparation of the aqueous phase 
FS75/SGClow 1.2% S75 and 0.3% SGC 
 
S75 and SGC were 
dispersed/dissolved in the aqueous 
phase by magnetic stirring over 
night 
FS75/SGChigh 1.8% S75 and 0.45% SGC 
FS75 3.2% S75 
Fpoloxamer/DCP 4% poloxamer 188 and 0.3% DCP 
Poloxamer was dissolved in the 
aqueous phase and DCP was 
melted with the triglyceride 
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After complete dispersion, the mixture was heated to about 90°C. The oil phase containing 
porphyrin was prepared by adding 500 µl from a methanolic stock solution (10 mg/ml) of 
porphyrin to the molten lipid and stirring at high temperature till the smell of methanol had 
disappeared. The hot aqueous phase was poured to the molten lipid and the mixture was 
pre-homogenized for one minute (Ultra-Turrax T8, IKA Labortechnic, Germany). This crude 
emulsion was transferred to the 90 °C warm high-pressure homogenizer Microfluidizer M-
110S (Microfluidics, US-Newton) and treated for 5 min at 700 bar. The hot colloidal emulsion 
was allowed to cool to 4°C. The second formulation from D118 was prepared as described 
above but by using 4% Mowiol, which was dissolved in the aqueous phase. According to 
these preparation conditions nanoparticles in the -form will be obtained [66-67]. These lipid 
nanoparticles in the -form were stored at refrigerator temperature. In an attempt to 
transform the particles to the -form, the nanoparticles of the two formulations were placed in 
a shaker water bath (Grant OLS 200, Cambridge, England) for 8 hours at 50°C with 100 
shakes/minute followed by storage at 23°C.  
 
3.2.3 Preparation of Miglyol 812 nanoemulsions 
Nanoparticles from 5% Miglyol 812 and 4% poloxamer 188 were prepared by 
homogenization at room temperature. Poloxamer 188 (1.2 g) was dissolved in the aqueous 
phase containing 2.25% glycerol and 0.01% thiomersal (27.3 g). The aqueous phase 
containing the surfactant was added to the oil phase (1.5 g Miglyol oil) and the mixture was 
pre-homogenized for 1 minute with an Ultra-Turrax (Ultra-Turrax T8, IKA, Germany) followed 
by homogenization with a Microfluidizer M-110S (Microfluidics, US-Newton) for 5 minutes at 
600 bar. The drug free nanoemulsion was used as acceptor in the transfer experiments with 
the ion exchange column technique. Loading with porphyrin (0.5 mg/ml) was conducted by 
direct addition of a methanolic stock solution (2.5 mg/ml) to the nanoemulsion followed by 
shaking for 24 hours at 25°C at 100 shakes/minute. This nanoemulsion was stored at room 
temperature. In order to obtain nanoemulsions with different zeta potential, five formulations 
of Miglyol nanoemulsion were prepared with different ratios between S75 and EPC (table 
3.3). S75 and EPC were dispersed in the aqueous phase (containing 2.25% glycerol and 
0.01% thiomersal) by magnetic stirring over night. The aqueous phase containing the 
surfactant was added to 10% Miglyol oil (3 g) and the mixture was pre-homogenized for  
1 minute with an Ultra-Turrax (Ultra-Turrax T8, IKA, Germany) followed by homogenization 
with a Microfluidizer M-110S (Microfluidics, US-Newton) at 600 bar for 5 minutes at room 
temperature. Loading with porphyrin (0.5 mg/ml) was done as described for the trimyristin 
donor nanoparticles. 
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Table 3.3: Composition of Miglyol nanoemulsions prepared with different ratios between Lipoid S75 
(S75) and egg phosphatidyl choline (EPC). The total emulsifier concentration was 2% (0.6 g) (all 
concentrations w/w) 
 
3.3 Preparation of the acceptor particles 
 
3.3.1 Preparation of the acceptor unilamellar vesicles  
Acceptor unilamellar vesicles were prepared using EPC and cholesterol in a molar ratio 
of 8:2 (EPC: cholesterol) [3, 68]. An EPC stock solution was prepared by dissolving 1.52 g in 
20 ml chloroform, a cholesterol stock solution by dissolving 0.194 g in 20 ml chloroform. The 
two lipid solutions (1 ml each) were mixed in a small bottom flask and dried to a thin film 
under vacuum (200 mbar for 2 hours followed by 30 mbar for 1 hour (Büchi Rotavapor R-
114, D-Essen)). The lipid film was rinsed with nitrogen and checked for the absence of any 
odour of solvent. The resulting thin film was hydrated by vortexing for 10 minutes with 1 ml 
tris buffer saline (10 mM tris, 140 mM NaCl, pH 7.4) to yield a lipid suspension with a 
concentration of 85 mg/ml. The lipid suspension was extruded through a 200 nm and then 
through a 100 nm polycarbonate membrane (Liposofast, Avestin, Canada) for 21 cycles. 
Unilamellar vesicles from Lipoid S75 (20 mg/ml) were prepared and extruded as described 
for the EPC and cholesterol vesicles. Radiolabeled unilamellar vesicles from EPC and 
cholesterol (8:2) were prepared using 3H-cholesteryl oleyl ether at a concentration of  
0.1 µCi/mg of the total vesicle lipids (8.5 µCi/ml) [56]. All these vesicles were stored at 
refrigerator temperature. 
 
3.3.2 Preparation of the acceptor multilamellar vesicles (MLV) 
MLV liposomes were prepared as described before [5]. 1 ml EPC chloroform stock 
solution (76 mg) was added to 1 ml cholesterol chloroform stock solution (9.68 mg) in a small 
bottom flask (the ratio between EPC and cholesterol being 8:2 mol/mol). The mixture was 
dried to a thin film under vacuum (200 mbar for 2 hrs to remove organic solvent and then 30 
Samples S75 EPC 
10% Miglyol oil (3 g) and 88% aqueous phase (26.4 g) 
MigS75/EPC1 1.5% (0.45 g) 0.5% (0.15 g) 
MigS75/EPC2 1.25% (0.375 g) 0.75% (0.225 g) 
MigS75/EPC3 1% (0.3 g) 1% (0.3 g) 
MigS75/EPC4 0.75% (0.225 g) 1.25% (0.375 g) 
MigS75/EPC5 0.5% (0.15 g) 1.5% (0.45 g) 
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mbar for 1 hr). The lipid film was rinsed with nitrogen for complete removal of the solvent. 
The lipid film was hydrated with 1 ml warm 300 mM sucrose solution under vortexing to yield 
MLV liposomes, which were transferred to a plastic Eppendorf tube. The mixture was 
centrifuged at 1600 xg for 10 min. After centrifugation, the MLV appeared as supernatant 
layer with the sucrose solution below. An 18G needle syringe was used to pierce the 
Eppendorf tube and to withdraw the sucrose solution. 0.5 ml of HBS pH 7.4 (20 mM Hepes, 
150 mM NaCl adjusted to pH 7.4 with 1 M NaOH) was added to the remaining MLV. The 
sample was vortexed and centrifuged at 1600 xg for 10 min, after that the MLV appeared as 
a pellet. The HBS supernatant was decanted and the pellet was washed twice with 0.5 ml 
HBS. The pellet was finally resuspended in fresh HBS (1 ml) and stored at refrigerator 
temperature.  
 
3.3.3 Preparation of the acceptor o/w emulsion droplets 
The acceptor o/w emulsion was composed of 5% (w/w) liquid medium chain 
triglycerides (Miglyol 812) stabilized with 3% (w/w) polyvinyl alcohol in an aqueous phase 
containing 2.25% glycerol and 0.01% thiomersal [6]. The emulsion was prepared at room 
temperature using an Ultra-Turrax (T8, IKA Labortechnic, Germany) for 15 minutes. The 
emulsion was stored at room temperature and used directly after preparation. For calibration 
of the flow cytometer, small fractions of the emulsions were loaded with different amounts of 
the investigated fluorescent dyes in the same way as described for the donor lipid 
nanoparticles. 
 
3.3.4 Preparation of the acceptor monoolein dispersions 
Six different monoolein dispersions with different amphiphile (monoolein + poloxamer) 
concentrations were prepared (table 3.4). Corresponding amounts of monoolein (MO) and 
poloxamer 407 were mixed in the melt and the molten mixture was added dropwise to water 
under stirring at room temperature [69]. The resulting coarse dispersions were equilibrated 
under magnetic stirring and protected from light for at least about 1 day at room temperature 
before homogenization in a microfluidizer M-110S (Microfluidics, US-Newton) at 350 bar for 
15 min at 40°C. After homogenization, fractions of the dispersions were autoclaved at 121°C 
in a laboratory autoclave (Varioklav, 65T, D-Oberschleissheim) for 15 min plus an 
equilibration time of 5 min. Autoclaving was used to transform vesicular structures potentially 
present in the dispersions into particles of cubic structure and to obtain particles of different 
sizes [18, 69]. 
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Table 3.4: Composition of the monoolein dispersions 
 
For calibration of the flow cytometer, stock solutions of the investigated fluorescent dyes 
were prepared in methanol in case of porphyrin or in ethanol in case of DiI. Different amounts 
from these stock solutions were added to different amounts from the acceptor cubic particles. 
Calibration curves between the concentration of the fluorescent dyes in the cubic particles 
and the fluorescence intensity were constructed.  
 
3.4 Characterization of the donor and acceptor particles 
 
3.4.1 Photon correlation spectroscopy (PCS) 
Particle sizes were measured by photon correlation spectroscopy (PCS) in a Zetasizer 
Nano (Malvern Instruments Ltd., UK-Worcestershire) after diluting the samples with filtered 
purified water at 25 °C and at a scattering angle 173°. Three consecutive measurements of 
5 min duration after 5 minutes of equilibration were recorded and the resulting z-average and 
polydispersity index (PDI) were averaged. The polydispersity index (PDI) presents an 
indication of the homogeneity of the samples. 
 
3.4.2 Laser diffraction (LD) 
The size of the different particles was determined using a laser diffractometer with 
PIDS technology (polarization intensity differential scattering), the Coulter LS 230 Particle 
Sizer (Beckman Coulter, D-Krefeld,). 8 consecutive measurements of 90 s (recorded without 
stirring) were averaged. The applied evaluation model used the Mie theory with a refractive 
index of 1.332 for water and 1.45 for the sample. The volume distributions of the samples 
were calculated and the results are given as the mean particle sizes. 
 
Amphiphile concentration % Monoolein (MO) % Poloxamer 407 
12 % poloxamer in amphiphile mixture and aqueous phase to 100% 
 
5%  4.4 0.6 
7%  6.2 0.8 
10%  8.8 1.2 
15%  13.2 1.8 
8 % poloxamer in amphiphile mixture and aqueous phase to 100% 
 
10%  9.2 0.8 
15%  13.8 1.2 
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3.4.3 Zeta potential measurements 
The zeta potential was measured with a Zetasizer Nano (Malvern Instruments Ltd., UK-
Worcestershire) after diluting the samples with 10 mM tris buffer pH 7.4. The results of three 
consecutive measurements each consisting of 20 runs were averaged. 
 
3.4.4 Differential scanning calorimetry (DSC) of the donor particles 
The physical state of the matrix lipid in the donor lipid nanoparticles was investigated in 
a DSC Pyris 1 (Perkin Elmer). Approximately 10 µl of the donor FS75/SGClow, 
FS75/SGChigh and FS75 before and after ultracentrifugation were measured at a scan rate 
of 5°C/min. An empty crucible was used as a reference. DSC of the supernatant layer 
(liposomal layer) after ultracentrifugation was also carried out. The measurements consisted 
of two heating runs and one cooling run ((1) 20°C to 65°C, (2) 65 to –10°C, (3) -10 to 65°C). 
Between heating and cooling an isothermal phase of 5 min was entered.  
The physical state and the polymorphic form (α-form or β-form) of the matrix lipid in the 
donor lipid nanoparticles, which were prepared from tristearin (D118), were investigated with 
the same sequences as the trimyristin nanoparticles except that the heating run was 
performed to 110°C.  
 
3.4.5 Cryo transmission electron microscopy (Cryo-TEM) 
Cryo-TEM images were performed by Dr. Frank Steiniger at the electron microscopic 
centre of the Friedrich Schiller University. A few microliters of the original nanoparticles 
(before ultracentrifugation), resuspended nanoparticles (after ultracentrifugation) and 
liposomal layer (supernatant layer after ultracentrifugation) of FS75/SGClow and 
FS75/SGChigh were placed on a holey grid (Quantifoil Micro Tools, Jena, Germany) and 
excess of liquid was removed with filter paper (the samples were used without dilution). The 
samples were cryofixed by rapid immersing into liquid ethane cooled to −170 °C to −180 °C 
in a cryobox (Carl Zeiss NTS GmbH, Oberkochen, Germany). Excess ethane was removed 
by blotting in the cold. The samples were transferred with a cryotransfer unit (Gatan 626-DH) 
into the pre-cooled cryoelectron microscope (Philips CM120, Netherlands) operated at 120 
kV and viewed under low dose conditions. 
 
3.4.6 31P- spectroscopy of the donor particles 
In order to investigate the existence of liposomes (small unilamellar vesicles) due to the 
presence of excess S75 in addition to the real triglyceride nanoparticles, 31P-NMR 
spectroscopy was carried out for the original nanoparticles (before ultracentrifugation), the 
resuspended nanoparticles (pellets after ultracentrifugation) and supernatant layer (excess 
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S75) of FS75/SGChigh and FS75 [70-72]. The 31P-NMR measurements were carried out by 
Dr. Wolfgang Günther at the institute of organic and macromolecular chemistry of the 
Friedrich Schiller University. The samples (500 µl) were analyzed by high-resolution 31P 
nuclear magnetic resonance (NMR) in a Bruker Avance 400 apparatus (Bruker, D-Karlsruhe) 
operating at a temperature of 30°C before and after the addition of an aqueous 
praseodymium chloride (PrCl3) solution (1 mg/ml). Deuterium oxide (D2O) was used as an 
external reference in a Wilmad NMR reference tube (2 mm), which was placed inside a 5 mm 
NMR sample tube containing the sample. In the paramagnetic shifted samples, 
praseodymium chloride solution was added in 1:5 (v/v) portions (100 µl praseodymium 
chloride and 400 µl sample). As a confirmatory experiment, 31P-NMR spectroscopy for 
unilamellar vesicles prepared from Lipoid S75 was performed. 
 
3.4.7 Determination of the lipid content by HPLC 
The amount of D114 in the original lipid nanoparticles (before ultracentrifugation), 
resuspended nanoparticles (after ultracentrifugation) and supernatant layer of FS75/SGClow, 
FS75/SGChigh and FS75 was determined using reversed-phase HPLC and evaporative light 
scattering detection (Varex MKIII ELSD, Alltech GmbH, D-Unterhaching). The analysis was 
performed with a 25 cm x 3 mm LiChrocart column packed with LiChrospher 100-5 RP 18 
(Merck KgaA, D-Darmstadt) in a System Gold 126 HPLC (Beckman Coulter GmbH, D-
Krefeld). Acetonitrile-tetrahydrofurane 55:45 (v/v) was used as mobile phase and the 
isocratic flow-rate was set at 1 ml/min. For the evaporation of the mobile phase, the 
temperature of the detector was adjusted at 91°C and the pressure was 2.2 l/min. These 
conditions were used all over the HPLC analysis. Standard solutions of D114 were prepared 
and the mean area under the curve was calculated to obtain a HPLC calibration curve for 
D114. To determine the amount of D114 in the nanoparticles a small amount of 
FS75/SGClow, FS75/SGChigh, FS75 and Fpoloxamer/DCP was dissolved in acetonitrile-
tetrahydrofurane 20:80 (v/v) to prepare 1 µl/ml samples and 100 µl of these solutions were 
injected into the HPLC for analysis. The amount of D114 in the samples was determined 
from the calibration curve.  
 
3.4.8 Drug content 
Since porphyrin was added to the D114 formulations before solidification and 
ultracentrifugation some drug was lost into the supernatant layer (excess S75) after 
ultracentrifugation. The amount of the drug in 20 µl ultracentrifuged and resuspended 
nanoparticles (pellets) and supernatant layer (for FS75/SGClow, FS75/SGChigh and FS75) 
was determined after diluting the samples to 5 ml with a mixture of acetonitrile-
tetrahydrofurane 20:80 (v/v) and measuring the UV absorbance at 421 nm. 
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3.4.9 Small angle diffraction of the acceptor monoolein dispersions 
To confirm the presence or absence of cubic particles in the different 
monoolein/poloxamer dispersions before and after autoclaving, small-angle X-ray 
diffractograms were recorded in a capillary sample holder for 1-2 h with a SWAX camera 
based on a Kratky collimator system (Hecus M. Braun, Optical Systems GmbH, Graz, 
Austria) with an Iso-Debyeflex 3003 60 kV generator (Seifert-FPM D-Freiberg), an X-ray tube 
(copper anode) FK 61-04 × 12 and equipped with two position sensitive detectors (PSD-50M, 
M. Braun, Garching, Germany).  
 
3.5 Drug transfer studies with the column method 
 
3.5.1 Calibration curves of the drug models in the different solvents 
For the calibration curve of porphyrin in ethanol, a stock solution of porphyrin was 
prepared by adding 1.02 mg porphyrin to 100 ml ethanol (10 µg/ml).  0.1, 0.2, 0.5, 1, 2, 3, or 
5 ml of this solution were diluted with ethanol to 25 ml to prepare solutions of 0.04, 0.08, 0.2, 
0.4, 0.816, 1.224 and 2.04 µg/ml. The absorbance of these solutions was measured at  
421 nm (Beckman, Du 640, U.S.A.).  
In the case of an acetonitrile-tetrahydrofurane mixture as solvent, a stock solution of 
porphyrin was prepared by adding 1.5 mg porphyrin to 100 ml of a mixture of acetonitrile-
tetrahydrofurane 20:80 (v/v). 15, 20, 50, 75, 150 or 175 µl of this solution were diluted with 
the solvent mixture to 10 ml to prepare solutions of 0.022, 0.03, 0.075, 0.112, 0.225 and  
0.27 µg/ml. The absorbance of these solutions was measured at 421 nm.  
In the case of Nile red, a stock solution was prepared by adding 0.4 mg Nile red to  
50 ml ethanol (8 µg/ml). 5, 10, 20, 30, 50, 100, 200, 300, 400, 500 or 600 µl of this solution 
were diluted with ethanol to 1 ml to prepare solution of 0.04, 0.08, 0.16, 0.24, 0.4, 0.8, 1.6, 
2.4, 3.2, 4 and 4.8 µg/ml. The absorbance of these solutions was measured at 548 nm. The 
Nile red calibration curve in the acetonitrile-tetrahydrofurane mixture was constructed as that 
in ethanol. A calibration curve for Di  was constructed in acetonitrile-tetrahydrofurane as 
described for Nile red but at wavelength 550 nm. Linear calibration curves with good 
correlation coefficients (R2 ≥ 0.999) were obtained in all cases (see appendix A.1). 
 
3.5.2 Preparation of the ion exchange columns 
A total of 50 ml of DEAE-Sepharose CL-6B was washed twice with a 3-fold excess of 
tris buffer saline (10 mM tris, 140 mM NaCl, pH 7.4). After each washing, the tris buffer was 
carefully decanted off and finally the gel was washed with a 3-fold excess of sucrose buffer 
(290 mM sucrose, 10 mM Trizma 7.4 pre-set crystals, 0.02% sodium azide, pH 7.4) and then 
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diluted 1:1 (v/v) with sucrose buffer, which was also used for the 
elution of the columns [3]. The column length was 5 cm with an 
inner diameter of 0.5 cm. An example of these columns is 
illustrated in figure 3.4. Some glass wool was placed at the bottom 
of the columns. About 1 ml ion exchange suspension (DEAE-
Sepharose) was filled in the column and the column was eluted 
with 2 ml sucrose buffer for packing and the eluate was discarded. 
The columns were lipid saturated (to reduce non-specific 
adsorption and to improve the recovery of acceptor particles) by 
applying 20 µl of the respective acceptor dispersion and eluting 
with 1.5 ml sucrose buffer [56]. This eluate was also discarded. In 
all experiments, the elution of the columns was performed using 1.5 ml sucrose buffer. 
 
3.5.3 Validation of the column method 
 
3.5.3.1 Acceptor recovery with radiolabeled unilamellar vesicles 
10 µl of the crystalline donor particles of FS75/SGClow, FS75/SGChigh and FS75 
before and after ultracentrifugation was added to Eppendorf tubes containing 100 µl of the 
radiolabeled unilamellar acceptor vesicles and 390 µl sucrose buffer. The Eppendorf tubes 
were incubated in a shaking water bath at 37°C. At appropriate time intervals (2, 4 and  
24 hours) 200 µl of the incubation mixture was placed on a mini-column containing DEAE-
Sepharose CL-6B. The eluent containing the radiolabeled unilamellar vesicles (1.5 ml) was 
diluted with 7 ml scintillation cocktail. The amount of radioactivity in the eluent was measured 
and the percentage of the eluted radiolabeled acceptor liposomes was determined. 
 
3.5.3.2 Charge transfer from the donor to the acceptor 
50 µl of the crystalline donor particles of FS75/SGChigh before and after 
ultracentrifugation was added to 500 µl of the acceptor neutral unilamellar vesicles (EPC: 
cholesterol 8:2) and the volume was completed to 2 ml with sucrose buffer. 
Ultracentrifugation (XL-80 ultracentrifuge, rotor type SW55 Ti, Beckman Coulter Inc., US-
Fullerton) of these mixtures was carried out at 35000 rpm, 15°C for 1 hour to separate the 
acceptor unilamellar vesicles (supernatant) from the crystalline donor particles (pellets). The 
zeta potential of both the supernatant (unilamellar vesicles) and the pellets (crystalline donor 
particles) was measured after diluting the samples with 10 mM tris buffer pH 7.4. 
 
 
 
Figure 3.4: Column 
used in the transfer 
experiments 
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3.5.3.3 Retention of the donor particles 
10 µl of the porphyrin loaded donor crystalline or liquid particles of FS75/SGClow, 
FS75/SGChigh and FS75 before and after ultracentrifugation was placed on the column after 
saturation of the column with 20 µl acceptor unilamellar vesicles. The columns were eluted 
with 1.5 ml of sucrose buffer. The eluate was collected directly into Eppendorf tubes and 
diluted to 5 ml with a mixture of acetonitrile-tetrahydrofurane 20:80 (v/v) and the UV 
absorbance was measured at 421 nm. 
 
3.5.4 Determination of the suitable zeta potential range for the column method 
10 µl of the five Miglyol formulations, which were prepared with different concentrations 
of EPC and S75 and loaded with porphyrin, was placed on the column after saturation of the 
columns with 20 µl Miglyol nanoemulsion free from porphyrin. The columns were eluted with 
1.5 ml of sucrose buffer. The eluate was collected directly into Eppendorf tubes, diluted to  
5 ml with ethanol and the UV absorbance was measured at 421 nm. 
 
3.5.5 Transfer of the different drug models to the acceptor unilamellar vesicles 
All transfer experiments to the different acceptors were carried out on the resuspended 
particles (after ultracentrifugation) in a crystalline or liquid form, which was prepared by 
melting the crystalline one. The transfer experiments from the crystalline and liquid donor 
particles of FS/75/SGClow, FS75/SGChigh and FS75 after ultracentrifugation to the acceptor 
unilamellar vesicles were carried out with molar ratios of 1:25 and 1:100 with different total 
lipid concentrations in the aqueous phase (transfer mixture). Different amounts of the donor 
particles were added to Eppendorf tubes containing different amounts of unilamellar vesicles 
and sucrose buffer (table 3.5). The Eppendorf tubes were incubated at 37°C. At appropriate 
time intervals 200 µl of the incubation mixture was placed on the ion exchange columns and 
eluted with sucrose buffer. The eluate was dissolved with a mixture of acetonitrile-
tetrahydrofurane 20:80 (v/v) and the UV absorbance was measured at 421 nm. To evaluate 
the effect of the lipid concentration on the drug transfer, the transfer of porphyrin from the 
resuspended nanoparticles of FS75/SGChigh to the acceptor unilamellar vesicles was also 
investigated at a low lipid concentration (5 mg/ml) and with a molar ratio of 1:100. 20 µl donor 
was added to a glass vial containing 800 µl SUV and 9180 µl sucrose buffer (total volume of 
the mixture was 10 ml). The glass vial was incubated in a shaking water bath for the intended 
times at 37°C and the remaining steps were continued as before.  
The transfer of Nile red and Di  from the resuspended nanoparticles of FS75/SGChigh 
to the acceptor unilamellar vesicles was done with a molar ratio of 1:100. 600 µl of the 
acceptor unilamellar vesicles and 385 µl of sucrose buffer were mixed in Eppendorf tubes, 
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then 15 µl of the crystalline donor particles was added to the mixture. The remaining steps 
were completed as described with porphyrin but the UV absorbance was measured at 548 
nm for Nile red and 550 nm for Di . 
 
Table 3.5: Amounts of the different donors (loaded with porphyrin) and acceptors in the transfer 
experiments, lipid molar ratios and the total lipid concentrations in the transfer mixture 
 
*
referring to the ratio between the trimyristin (calculated after ultracentrifugation by HPLC) and the 
different lipid in the acceptors excluding the surfactants (e.g. lipoid S75, SGC and poloxamer) 
 
3.5.6 Transfer to the acceptor monoolein dispersions and Miglyol nanoemulsion 
The transfer of porphyrin from the resuspended nanoparticles of FS75/SGChigh to the 
acceptor monoolein dispersions (molar ratio 1:25) and the Miglyol nanoemulsion (molar ratio 
1:100) was also studied. The acceptor monoolein dispersions used in these studies were 
prepared with 5% amphiphile (monoolein and poloxamer) without and with autoclaving. As a 
preliminary experiment, the recovery of the acceptor particles was measured by adding  
Donor 
volume (µl) 
Acceptor volume 
(µl) 
Sucrose buffer 
volume (µl) 
Lipid molar 
ratios
* 
Total lipid concentration 
(mg/ml)
*
 
FS75/SGClow donor and acceptor unilamellar vesicles  
10 95 395 1:25 17 
10 380 110 1:100 65 
FS75/SGChigh donor and acceptor unilamellar vesicles  
10 100 390 1:25 18 
10 400 90 1:100 68 
60 600 340 1:25 50 
15 600 385 1:100 50 
FS75 donor and acceptor unilamellar vesicles  
10 95 395 1:25 17 
10 380 110 1:100 65 
FS75/SGChigh donor and acceptor monoolein dispersions (5% amphiphile) in the form of vesicles 
or cubic particles  
100 1000  1:25 48 
FS75/SGChigh donor and acceptor Miglyol nanoemulsion  
20 1000  1:100 50 
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200 µl of the acceptor that was loaded with porphyrin, to the ion exchange columns. The 
eluate was dissolved by using a mixture of acetonitrile-tetrahydrofurane 20:80 (v/v) and the 
UV absorbance was measured at 421 nm. 
For the transfer experiments, different amounts (table 3.5) of the donor nanoparticles were 
added to Eppendorf tubes containing 1 ml of the acceptor particles (monoolein dispersions 
and Miglyol nanoemulsion) and the remaining steps were done as described with the 
acceptor unilamellar vesicles.  
Di  transfer from the resuspended nanoparticles of FS75/SGChigh to the acceptor 
cubic nanoparticles, which were prepared from 5% amphiphile, was investigated with molar 
ratios of 1:25 and 1:100. Different amounts of the donor nanoparticle dispersions (25 and 
100 µl for the molar ratio 1:100 and 1:25, respectively) were added to Eppendorf tubes 
containing 1 ml of the cubic nanoparticles. The remaining steps were done as described with 
porphyrin. 
 
3.5.7 Porphyrin affinity to monoolein dispersions and unilamellar vesicles  
To compare the affinity of porphyrin to the acceptor monoolein dispersions before or 
after autoclaving (5% amphiphile, vesicles or cubic particles) and the acceptor unilamellar 
vesicles, 4 ml of the respective acceptors was added to glass vials each containing 10.7 mg 
of porphyrin (porphyrin in excess). At different time points, 500 µl dispersion from each glass 
vial was filtered through 0.45 µm filters. 50 µl of the filtrate was dissolved in a mixture of 
acetonitrile-tetrahydrofurane 20:80 (v/v) and the UV absorbance was measured at 421 nm.  
 
3.6 Drug transfer studies with the centrifugation method 
 
3.6.1 Transfer of different drug models to the acceptor multilamellar vesicles (MLV) 
The transfer of porphyrin was studied from the donor resuspended nanoparticles in the 
liquid form, which was prepared by melting the crystalline form of FS75/SGClow, 
FS75/SGChigh, FS75 and from the original lipid nanoparticles of Fpoloxamer/DCP to the 
acceptor MLV particles. Different amounts of the donor (table 3.6) were added to Eppendorf 
tubes containing 600 µl of the acceptor MLV and different amounts of HBS (the total volume 
was 1 ml). The samples were incubated in a shaking water bath at 37 °C. Samples were 
taken at specific times, vortexed and centrifuged (3MK centrifuge, Sigma, D-Osterode) at 
5300 rpm (1600 x g) for 10 min to separate the nanoparticles from the pellet MLV liposomes. 
The supernatant (nanoparticles) was collected by decantation and the absorbance was 
measured at 421 nm after dilution with a mixture of acetonitrile-tetrahydrofurane 20:80 (v/v) 
to 5 ml. 
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Table 3.6: Amount (µl) of the different donor particles mixed with 600 µl MLV acceptor to obtain 
different lipid molar ratios in the transfer experiments with the centrifugation method. The total lipid 
concentration in the transfer mixtures was 50 mg/ml 
 
The MLV containing pellet was washed twice with 250 µl HBS, vortexed and centrifuged (the 
centrifugation time for each washing was 10 min). The first and second washings were 
combined and the absorbance was measured at 421 nm after dilution with the same solvent 
mixture to 5 ml. The amount of drug detected in the supernatant and washes was combined 
to obtain an overall supernatant amount. The percent drug retained in the nanoparticles was 
[(Amount of drug in supernatant)/ (total amount of drug in the donor at time = 0)] × 100. 
The amount of drug at time zero was determined by diluting the respective amount of 
the donor dispersion to 5 ml with a mixture of acetonitrile-tetrahydrofurane 20:80 (v/v) and 
measuring the UV absorbance at 421 nm. The amount of the drug in the MLV was 
determined by dissolving the MLV pellets in ethanol, diluting to 5 ml and measuring UV 
absorbance at 421 nm.  The percent drug transferred was [(Amount of drug in MLV pellets)/ 
(total amount of drug in the donor at time = 0)] × 100. 
The porphyrin transfer from Fpoloxamer/DCP to the acceptor MLV in the presence of 
3% PVA was studied by adding 10 µl of the donor particles to Eppendorf tubes containing 
385 µl HBS and 600 µl MLV acceptor with 3% PVA. The Eppendorf tubes were incubated in 
a shaking water bath at 37°C. The other steps of the transfer experiment were performed as 
described before. The transfer of Nile red from the resuspended liquid nanoparticles of 
FS75/SGChigh to the acceptor MLV was studied with a molar ratio of 1:100. 15 µl donor 
particles were added to Eppendorf tubes, which contained 385 µl HBS and 600 µl MLV. The 
Donor Donor volume (µl) Lipid molar ratios 
FS75/SGClow 
64 1:25 
32 1:50 
16 1:100 
FS75/SGChigh 
60 1:25 
30 1:50 
15 1:100 
FS75 
64 1:25 
32 1:50 
16 1:100 
Fpoloxamer/DCP 
40 1:25 
20 1:50 
10 1:100 
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transfer procedures were done as described before with porphyrin and the UV absorbance 
was measured at 548 nm. 
 
3.6.2 Transfer of different drug models to the acceptor o/w emulsion 
The transfer of porphyrin from the resuspended crystalline nanoparticles of 
FS75/SGChigh and the original crystalline nanoparticles of Fpoloxamer/DCP to the acceptor 
o/w emulsion was studied with a molar ratio of 1:25. Different amounts of the crystalline 
loaded donor particles (80 µl of FS75/SGChigh and 60 µl of Fpoloxamer/DCP) were mixed 
with 1 ml of the acceptor o/w emulsion in Eppendorf tubes. The Eppendorf tubes were 
incubated in a shaking water bath at 37°C. After shaking, the samples were diluted with 3 ml 
purified water into an ultracentrifugation tube. The samples were ultracentrifuged (XL-80 
ultracentrifuge, rotor type SW55 Ti, Beckman Coulter Inc., US-Fullerton) for 30 minutes at 
45000 rpm to separate the crystalline donor from the acceptor emulsion. After removing the 
cream layer and aqueous supernatant the pellet was scraped from the tube bottom, 
resuspended in 250 µl of water and sonicated for 2 min. The suspension was transferred into 
glass vials and the centrifugation tube was rinsed with 250 µl water, which was added to the 
glass vials. The pellet suspension was dissolved in 3 ml of a mixture of acetonitrile-
tetrahydrofurane 20:80 (v/v) and the UV absorbance was measured at 421 nm.  
The transfer of Nile red from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor o/w emulsion was studied with a molar ratio of 1:100. 20 µl of 
the donor particles was mixed with 1 ml of the acceptor o/w emulsion in Eppendorf tubes. 
The other steps of the transfer experiment were done as before and the UV absorbance of 
Nile red was measured at 548 nm.  
 
3.6.3 Transfer of different drug models to the acceptor cubic particles 
The transfer of porphyrin from the resuspended nanoparticles of FS75/SGChigh to the 
acceptor cubic particles with different particle sizes was investigated with a molar ratio of 
1:25. 100 µl of the donor was mixed with different amounts of the acceptor (1 and 0.5 ml in 
case of cubic particles prepared with 5 and 10% amphiphile, respectively) in Eppendorf tubes 
and shaken at 37°C (100 shakes/minute). After shaking, the donor and acceptor were 
separated as described before with the acceptor o/w emulsion. The UV absorbance of the 
pellets (dissolved in a mixture of acetonitrile-tetrahydrofurane) was measured at 421 nm.  
The Di  transfer from the resuspended nanoparticles of FS75/SGChigh to the acceptor 
cubic particles, prepared from 5% amphiphile, was studied with molar ratios of 1:25 and 
1:100. 100 or 25 µl of the donor particles were mixed with 1 ml of the acceptor cubic particles 
in Eppendorf tubes to achieve molar ratios of 1:25 and 1:100, respectively. The other steps 
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of the transfer experiment were done as before and the UV absorbance of Di  was measured 
at 550 nm.  
 
3.7 Drug transfer studies with the flow cytometry method 
 
3.7.1 General procedure 
The measurements were performed in a similar way as described previously [6]. To 
select the conditions for the fluorescence measurements, the acceptor particles (cubic 
particles, o/w emulsion and MLV) were measured (without drug) in the flow cytometer (Epics 
XL MCL, Beckman Coulter Inc., US-Fullerton). Different amounts of the acceptor dispersions 
were diluted with purified water in a measurement tube and subsequently measured by flow 
cytometry. The right amount of the acceptors was achieved when a count rate of 
approximately 250 events per second was reached. After the detection of 10,000 events the 
measurements were stopped. The emitted fluorescence of porphyrin and Nile red was 
detected at the photomultiplier tube number 4 (FL4) with a wavelength range of 665-685 nm 
while the emitted fluorescence of Di  was detected at FL2 (565-585 nm). The flow cytometer 
was calibrated by measuring the fluorescence intensity of acceptor samples, which had been 
loaded with defined amounts of the drug models and the fraction of drug transferred was 
calculated from the resulting calibration curves. Between the measurements, cleaning steps 
were introduced to avoid mixing with residual particles of preceding samples. 
 
3.7.2 Calibration curves of the drug models with the different acceptors  
In case of the acceptor MLV, 6 samples of the MLV acceptor containing porphyrin were 
prepared with the same procedures as used for the preparation of the MLV without drug 
except that small amounts of stock solution of porphyrin in methanol were added to the 
chloroform solution of the EPC and cholesterol. Due to the loss of some drug during the 
preparation of MLV, the final amount of the drug in the MLV was determined by UV 
spectroscopy after dissolving the MLV in ethanol. 3-5 µl of these porphyrin loaded MLV 
formulations were diluted with 1 ml water and measured by flow cytometry. A calibration 
curve between the porphyrin concentrations in the MLV acceptor and the fluorescence 
intensity was constructed. 
With the acceptor o/w emulsion, a stock solution of porphyrin (10 µg/ml) was prepared 
in ethanol. Different amounts of this stock solution were taken and added to different 
amounts of acceptor emulsion to prepare emulsion loaded with different amounts of drug (0.1 
to 1 µg/ml) followed by shaking in a shaker water bath at 25°C for 1 day. 10-15 µl of these 
mixtures were diluted with 1 ml water and measured by flow cytometry. The calibration 
curves of the other dyes in the different acceptors were performed as described for porphyrin 
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with the acceptor emulsion. For all drug models and acceptor under investigation, linear 
calibration curves with good correlation coefficients (R2 ≥ 0.997) were obtained (see appendix 
A.2). 
 
3.7.3 Porphyrin and Nile red transfer to the acceptor MLV 
The transfer of porphyrin was investigated by adding different amounts of the loaded 
donor particles of Fpoloxamer/DCP in the liquid form (40, 20 and 10 µl for molar ratios of 
1:25, 1:50 and 1:100 respectively) to Eppendorf tubes containing 600 µl MLV acceptor 
dispersion and different amounts of HBS (total mixture volume was 1 ml). The tubes were 
subsequently incubated in a water bath shaker at 37 °C. Samples were collected at different 
time points after mixing. 3 to 5 µl of the mixture were diluted in 1 ml purified water and 
subsequently measured at the flow cytometer. 
The transfer of Nile red from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor MLV was studied as described for porphyrin by mixing 15 µl 
of the loaded donor particles with 600 µl MLV acceptor and 385 µl HBS in Eppendorf tubes 
(molar ratio 1:100). 
 
3.7.4 Porphyrin and Nile red transfer from different donors to the o/w emulsion 
The transfer of porphyrin and Nile red was investigated by mixing different amounts of 
the loaded donor particles (specified in table 3.7) with 1 ml of the acceptor o/w emulsion in 
Eppendorf tubes. The other steps of the transfer experiment were performed as described 
with the acceptor MLV except that 10 to 15 µl of the transfer mixture were diluted in 1 ml 
purified water and subsequently measured at the flow cytometer.  
 
3.7.5 Porphyrin and Di  transfer to the acceptor cubic particles 
The transfer of porphyrin and Di  from the resuspended crystalline nanoparticles of 
FS75/SGChigh to two acceptor cubic particles with different particle sizes was studied with a 
molar ratio of 1:25 in case of porphyrin while with Di  the molar ratio was 1:25 and 1:100. The 
experiments were done with the acceptor cubic particles (after autoclaving), which were 
prepared from 15 % amphiphile with 12 and 8% poloxamer (particle size > 1 µm). Different 
amounts of donor particles (125 and 31 µl of the donor particles loaded with Di  and 125 µl of 
porphyrin donor particles) were added to Eppendorf tubes containing 400 µl acceptor cubic 
particles and different amounts of water (total mixture volume was 1 ml). The other steps of 
the transfer experiment were performed as described with the acceptor MLV except that 10 
to 15 µl of the transfer mixture were diluted in 500 µl purified water and subsequently 
measured at the flow cytometer.  
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Table 3.7: Amount (µl) of the different donor particles mixed with 1 ml acceptor o/w emulsion to obtain 
different lipid molar ratios in the transfer experiments with the flow cytometric method. The total lipid 
concentration in the transfer mixtures was 50 mg/ml 
 
3.8 Transfer kinetics  
The data points of the percental transferred amount of the different drug models to the 
different acceptors with the three transfer methods were exponentially fitted using Microcal 
Origin 6.0 software (OriginLab Corporation, US-Northampton) and the exponential function: 
Aacc = Afinal – A  e
 – k  t [1] 
Aacc is the percental amount of fluorescent dye transferred to the acceptor particles at time t, 
Afinal is the final percental transferred amount of dye and marks the height of the plateau, A is 
a pre-exponential coefficient and K is the rate constant of the transfer. All transfer kinetics 
values (transfer rate constant and the final percent transferred) were obtained from the fitted 
curves and the equilibrium time was determined by calculating the time at which 99% of the 
plateau was reached.  
 
Donor Volume of the donor (µl) 
Molar 
ratios 
Resuspended crystalline nanoparticles of FS75/SGChigh 
loaded with porphyrin 
80 1:25 
40 1:50 
20 1:100 
Fpoloxamer/DCP in the liquid or crystalline form  
loaded with porphyrin 
60 1:25 
30 1:50 
15 1:100 
Miglyol nanoemulsion loaded with porphyrin 10 1:100 
Resuspended crystalline tristearin nanoparticles in the 
different physical forms loaded with porphyrin 
18 1:100 
Monoolein vesicles (5% amphiphile)  
loaded with porphyrin 
10 1:100 
Monoolein cubic particles (5% amphiphile)  
loaded with porphyrin 
10 1:100 
Resuspended crystalline nanoparticles of FS75/SGChigh 
loaded with Nile red 
20 1:100 
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Chapter 4: Results and discussion 
 
4.1 Characterization of the donor particles 
 
4.1.1 Particle size and zeta potential of D114 nanoparticles 
Figure 4.1 shows the particle size of the D114 nanoparticles stored at room and 
refrigerator temperature. The nanoparticles stored at refrigerator temperature had a higher 
particle size because the recrystallization of the colloidally dispersed trimyristin is 
accompanied by the formation of platelet-like colloidal crystals. These anisometric particles 
have a larger hydrodynamic diameter in PCS compared with the corresponding spherical 
nanoemulsion particles [35, 42, 73]. 
 
It was reported earlier [39] that colloidal emulsions and lipid nanoparticles that were 
prepared by the homogenization process and with phospholipids as emulsifier contain a 
significant amount of small unilamellar vesicles (SUV) due to the excess emulsifier 
(phospholipid) used. The transfer experiments were intended to be done from the lipid 
nanoparticles to the different acceptors. According to this requirement, it was important to 
separate the lipid nanoparticles from the excess phospholipid. Thus, after crystallization of 
the lipid nanoparticles, the formulations that were prepared with the emulsifier Lipoid S75 
were treated by ultracentrifugation in an attempt to remove excess phospholipid into the 
Figure 4.1: PCS z-average mean particle size (bars) and polydispersity indices (PDI, circles) of the 
four D114 formulations stored at room and refrigerator temperature (n = 3).  
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supernatant [70-72]. The ultracentrifugation process was carried out on FS75/SGClow, 
FS75/SGChigh and FS75 only. Figure 4.2 illustrates the particle size of the resuspended lipid 
nanoparticles (pellets after ultracentrifugation). The dispersions had an acceptable PDI, 
which indicates the homogeneity of the resuspended nanoparticles. The particle size of the 
resuspended nanoparticles (pellets) was larger than that of the original nanoparticles (before 
ultracentrifugation) and this could be explained by the loss of the excess S75 emulsifier, 
which might lead to the aggregation of the nanoparticles. The particle size and PDI of the 
resuspended nanoparticles containing the drug models was nearly the same as without 
(figure 4.3). 
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Figure 4.3: PCS z-average mean particle size (bars) and polydispersity indices (PDI, circles) of 
resuspended D114 lipid nanoparticles (crystalline nanoparticles after ultracentrifugation) loaded with 
the drug models porphyrin, Nile red and Di  (n = 3). 
 
 
Figure 4.2: PCS z-average mean particle size (bars) and polydispersity indices (PDI, circles) of the 
three D114 formulations before and after ultracentrifugation (n = 3). 
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Figure 4.4 shows the particle size of FS75/SGClow, FS75/SGChigh and FS75 before 
and after ultracentrifugation as obtained from LD-PIDS measurements. There were no 
particles in the micrometer (µm) size range and all crystalline lipid nanoparticles before and 
after ultracentrifugation were located in the nanometer (nm) size range with a good 
homogeneity. Only the resuspended nanoparticles of FS75 contained a very small fraction of 
microparticles. These small amounts of large particles did not appear in the original 
formulation before ultracentrifugation indicating that they were formed during the 
ultracentrifugation/redispersion process. The LD-PIDS results confirmed the PCS data where 
a slight increase in the particle size after ultracentrifugation was observed.  
 
Also the zeta potential of the four formulations was determined. As shown in figure, 4.5, 
the zeta potential of Fpoloxamer/DCP was low (-14 mV). This low zeta potential may be due 
to the presence of poloxamer on the surface of the nanoparticles so that DCP molecules 
could probably not reach the interface in the required position in order to obtain negatively 
charged nanoparticles. In other words, the presence of poloxamer hindered the localization 
of DCP in the surface of the nanoparticles and thus DCP molecules could not give a negative 
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Figure 4.4: LD-PIDS particle size distributions of the original crystalline nanoparticles (before 
ultracentrifugation) and the resuspended crystalline nanoparticles (pellets after ultracentrifugation) 
a) FS75/SGClow, b) FS75/SGChigh and c) FS75.  
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charge to the nanoparticles. Negatively charged donors were, however, important for the 
nanoparticles to be suitable for the transfer experiments with the column technique. The high 
zeta potential of FS75/SGClow, FS75/SGChigh and FS75 could be attributed to the 
presence of S75. In spite of the neutral charge of Lipoid S75, the negative potential can be 
attributed to the presence of fatty acids in its composition [74]. As a confirmatory experiment, 
the zeta potential of small unilamellar vesicles prepared from S75 only was measured and it 
was –50 mV  2.1. This result was in agreement with the high zeta potential that was 
observed with FS75, which was prepared from Lipoid S75 only. The zeta potential of 
FS75/SGClow and FS75/SGChigh was higher than that of FS75 and this may be due to the 
presence of the anionic emulsifier SGC in these formulations.  
 
 
 
 
4.1.2 DSC of D114 nanoparticles 
 
The objective of this study was concerned with the release and transfer behaviour of 
different drug models from the lipid nanoparticles, especially those in the crystalline form. 
From this point of view, monitoring of the crystalline status was a crucial point and was 
carried out by DSC measurements. Another important aim of these DSC measurements was 
to determine the effect of the ultracentrifugation/redispersion process on the crystalline lipid 
nanoparticles. Figure 4.6 shows the DSC melting curves of FS75/SGClow, FS75/SGChigh 
and FS75 before and after ultracentrifugation. The DSC curves of the resuspended 
nanoparticles indicated that these particles were in a crystalline form. For more detailed 
evaluation, sum curves of the resuspended nanoparticles and supernatant layer curves were 
Figure 4.5: Zeta potential of the four D114 formulations before (original nanoparticles) and after 
(resuspended nanoparticles) ultracentrifugation (n = 3).  
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constructed for FS75/SGClow, FS75/SGChigh and FS75. By comparing these sum curves 
with the melting curves of the original crystalline nanoparticles before ultracentrifugation a 
Figure 4.6: DSC heating curves of the original crystalline lipid nanoparticles before 
ultracentrifugation; resuspended nanoparticles after ultracentrifugation (pellets) and the supernatant 
layer of FS75/SGClow, FS75/SGChigh and FS75 stored at refrigerator temperature. The small right 
panel graphs are the sum curves of the resuspended nanoparticles and supernatant curves of 
FS75/SGClow, FS75/SGChigh and FS75. 
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high similarity was observed. This similarity indicated that there was no change in the 
nanoparticles after ultracentrifugation. DSC of the supernatant layers was carried out to 
determine if these layers contain crystalline trimyristin lipid nanoparticles or not. According to 
figure 4.6, these supernatant layers did contain crystalline particles. Obviously, these 
particles were very small because the melting transition was broadened and displayed 
several melting maxima [42] as compared to the melting curves of the resuspended 
nanoparticles. These small particles could not be separated into the pellets during the 
ultracentrifugation process. The graphs displayed in figure 4.6 are a good illustration of the 
fact that the melting behaviour of triglyceride nanoparticles strongly depends on particle size 
[42]. Particles in coarser dispersions melted in a single transition with a maximum slightly 
below that of the bulk material reflected in the melting behaviour of the crystalline 
resuspended nanoparticles (particle size was about 140-145 nm). On contrary to the 
resuspended nanoparticles, the melting curves of the original crystalline nanoparticles before 
ultracentrifugation (particle size was about 115-120 nm) and the melting curves of the 
supernatant layers (particle size was about 90-100 nm) displayed several distinct melting 
maxima (stepwise melting) according to figure 4.6. This stepwise melting is most probably 
due to the subsequent melting of classes of particles with different platelet heights (different 
particle thicknesses) [42, 75-77].  
 
4.1.3 Cryo transmission electron microscopy (Cryo-TEM) of D114 nanoparticles 
Figure 4.7 shows cryo-TEM images of the crystalline lipid nanoparticles of 
FS75/SGClow and FS75/SGChigh before and after ultracentrifugation. In this figure, the 
presence of weak circular and ellipsoidal structures, which represent thin platelets in top 
view, can be observed. If the particles are viewed edge-on, they appear as dark rods or 
needles since, in this position, the increased thickness of the structures leads to a darker 
appearance [39, 78]. According to figure 4.7, the presence of these structures could be 
observed in all investigated samples, including the supernatant layer. These results were in 
agreement with the DSC data, which illustrated the loss of nanoparticles into the 
supernatant. A small amount of liposomal structures could be observed in the images of the 
supernatant layer (figure 4.7 (a)) where they appeared as small spherical structures or ring 
shaped structures. These liposomal structures could not, however, be observed in figure 4.7 
b and c, the images of resuspended nanoparticles (pellets) after ultracentrifugation and the 
original lipid nanoparticles (before ultracentrifugation). In case of the original nanoparticles, 
the liposomal structure may not be observable due to the abundance of the crystalline 
nanoparticles in the medium. In the images of the resuspended nanoparticles, the lack of 
these liposomal structures might be correlated with their removal after the ultracentrifugation 
process.  
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(a) 
(b) 
(c) 
Figure 4.7: Cryo-TEM images of FS75/SGClow (left panel) and FS75/SGChigh (right panel); a) 
supernatant layer; b) resuspended nanoparticles (pellets) after ultracentrifugation; c) original 
nanoparticles before ultracentrifugation. The bar represents 200 nm. 
Nanoparticles (top view) Nanoparticles (edge view) 
Liposomes 
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4.1.4 31P- spectroscopic investigation of D114 nanoparticles 
31P-NMR spectroscopy was used to confirm the presence of liposomes due to excess 
S75 in the prepared nanoparticles and to determine the distribution of the phospholipid 
between the triglyceride nanoparticles and the liposomes. As reported before, small 
phospholipid-containing structures, such as micelles and sonicated vesicles, lead to relatively 
narrow, symmetrical 31P-NMR lines [79-80]. Unsonicated phospholipid bilayers (large 
multilamellar structures or large unilamellar liposomes), on the other hand, exhibit broad, 
unsymmetrical lines. Figure 4.8 shows the NMR spectra of FS75/SGChigh and FS75 
(original nanoparticles before ultracentrifugation, resuspended nanoparticles and supernatant 
layer). Two signals with different line shapes can be observed in the original nanoparticles 
(figure 4.8 (a)). A larger and sharper signal (around 0 ppm) was attributed to phospholipid 
headgroups in a more hydrophilic environment (liposomes formed by the excess S75). The 
broader zone of resonance (around 5 ppm) was attributed to the phospholipid headgroups in 
a lipophilic environment, which belong to the phospholipid coat of the trimyristin 
nanoparticles. The sharp signal at 0 ppm, which represents the phospholipid of the 
liposomes, was lost after centrifugation and only the broader signal (the phospholipid coat of 
the trimyristin nanoparticles) was found in the resuspended nanoparticles (figure 4.8 (b)). 
Both signals (the sharp and the broad one) were observed in the supernatant layer after 
ultracentrifugation, which indicates the presence of the two populations of the phospholipid 
(phospholipid coat of the triglyceride particles and phospholipid in liposomes due to the 
excess S75) (figure 4.8 (c)).  
To confirm that the sharp signal corresponds to the liposomes (from excess S75) and 
the broad signal corresponds to the phospholipid coat of the triglyceride particles 
praseodymium chloride (PrCl3) was added to the different dispersions as a shifting reagent. 
PrCl3 only interferes with the accessible phospholipid (phospholipid of the outer liposomes 
layer and phospholipid coat of the triglyceride nanoparticles) but not with the inner 
phospholipid layer of liposomes.  
31P-NMR measurements in the presence of PrCl3 reveal that the sharp peak was still 
present in the case of the original formulations before ultracentrifugation but the intensity of 
this peak was smaller than without PrCl3 (figure 4.8 (a) right panel). This decrease in the 
intensity was due to the shift of the signal of the accessible phospholipid headgroups and 
only this sharp peak is related to the inaccessible phospholipid headgroups belonging to the 
inner phospholipid layer of liposomes. The broad peak was shifted to about 10 ppm. 
Corresponding results were obtained with the supernatant layer after the ultracentrifugation 
process, which indicates the presence of triglyceride nanoparticles as well as liposomes in 
this supernatant layer (figure 4.8 (c) right panel). In case of the resuspended nanoparticles 
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(pellets) the broad peak related to the phospholipid coat of the triglyceride nanoparticles was 
shifted to about 10 ppm (figure 4.8 (b) right panel).  
The results obtained from 31P-NMR spectroscopy after addition of the shifting reagent 
confirm the results that were obtained without PrCl3, which indicate that the sharp signal is 
related to the liposomes while the broad signal is related to the phospholipid coat of the 
triglyceride nanoparticles. The loss of the sharp signal after ultracentrifugation indicates that 
the excess S75 liposomes were removed by the ultracentrifugation technique. Although 
ultracentrifugation is a good technique to separate the excess S75 liposomes from the 
nanoparticles, it led to the loss of a fraction of triglyceride nanoparticles as observed from the 
presence of the broad signal in the supernatant layer, which belongs to the phospholipid coat 
of the triglyceride nanoparticles. NMR data suggest the existence of SUV in addition to the 
triglyceride nanoparticles in the systems prepared by using S75 as a surfactant. NMR 
analysis confirmed the results that were observed before with DSC and cryo-TEM, which 
showed the presence of a fraction the triglyceride nanoparticles in the supernatant layer.  
As a confirmatory experiment, 31P-NMR spectroscopy of the small unilamellar vesicles, 
which were prepared from S75 only, was performed. A sharp signal at about 0 ppm (figure 
4.9 (a)) was observed as detected before with the lipid nanoparticle formulations confirming 
that this sharp signal is due to phospholipid headgroups in a more hydrophilic environment 
(S75 liposomes). Two signals were observed after mixing the small unilamellar vesicles with 
the resuspended crystalline nanoparticles of FS75/SGChigh (figure 4.9 (b)). The two signals 
were the sharp signal belonging to the phospholipid headgroups of the S75 unilamellar 
vesicles, and the broader signal attributed to the phospholipid headgroups in a lipophilic 
environment (phospholipid coat of the triglyceride nanoparticles). Shifting of this broader 
signal in the mixture between the small unilamellar vesicles and the resuspended crystalline 
nanoparticles was observed after the addition of PrCl3 (figure 4.9 (c)). 
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Figure 4.8: 
31
p-NMR spectra of the crystalline lipid nanoparticles of FS75/SGChigh and FS75; (a) 
original nanoparticles before ultracentrifugation; (b) resuspended nanoparticles or pellets; (c) 
supernatant layer; without PrCl3 (left panel) and with PrCl3 (right panel). 
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4.1.5 Determination of the lipid content by HPLC 
Since the ultracentrifugation process may lead to a loss of triglyceride from the 
formulations, a determination of the real D114 content in the nanoparticles formulations was 
performed. Determination of the lipid content in the lipid nanoparticles was carried out by 
HPLC with an evaporative light scattering detector (ELSD). The HPLC analysis of D114 
showed a distinct peak at about 2 minutes (figure 4.10). The plot of the peak area versus 
sample concentration in double logarithmic coordinates gave a linear correlation, which 
showed a good correlation coefficient (R2) = 0.999 (figure 4.11). 
 The content of trimyristin in FS75/SGClow, FS75/SGChigh, FS75 and 
Fpoloxamer/DCP before and after ultracentrifugation was determined from the calibration 
curve. The amount of trimyristin remaining in the redispersed nanoparticle suspensions after 
ultracentrifugation was 67%, 77% and 72% for FS75/SGClow, FS75/SGChigh and FS75 
respectively (table 4.1). The low trimyristin content in FS75/SGClow after ultracentrifugation 
may be attributed to the filtration of this formulation (the amount before filtration was  
37.5 mg/ml and the percentage was 75%). According to the HPLC analysis of the 
supernatant layers of the three nanoparticle formulations about 20% of the trimyristin was 
lost into the supernatant during the ultracentrifugation process. This is in agreement with the 
results of DSC, cryo-TEM and NMR measurements; all showed that the supernatant layer 
contained a fraction of the crystalline lipid nanoparticles (the very small particles).  
 
 
Figure 4.9: 
31
p-NMR spectra; a) phospholipid S75 
unilamellar vesicles; b) mixture of the resuspended 
nanoparticles of FS75/SGChigh and S75 unilamellar 
vesicles; (c) mixture of the resuspended 
nanoparticles and S75 unilamellar vesicles after the 
addition of PrCl3. 
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Table 4.1: Concentration of the matrix lipid trimyristin (D114) in the original samples (before 
ultracentrifugation), resuspended nanoparticles (pellets) and the supernatant layer of FS75/SGClow, 
FS75/SGChigh, FS75 and Fpoloxamer/DCP as determined by HPLC 
 
a
 Fpoloxamer/DCP was not subjected to ultracentrifugation because it does not contain the 
phospholipid S75 as emulsifier. 
 
4.1.6 Drug content 
Table 4.2 shows the drug distribution between the resuspended crystalline lipid 
nanoparticles of FS75/SGClow, FS75/SGChigh and FS75 after ultracentrifugation and the 
corresponding supernatant layers. According to these results the drug affinity is higher for 
Formula 
Concentration of D114 
mg/ml 
% of D114 in relation to 
the original samples 
Original samples 
FS75/SGClow 50.25  0.12 - 
FS75/SGChigh 50.75  0.2 - 
FS75 45.5  0.03 - 
Fpoloxamer/DCP
 a 
50.9  0.5  
Resuspended 
particles (pellets) 
FS75/SGClow 33.5  0.15 67% 
FS75/SGChigh 39  0.18 77% 
FS75 32.8  0.11 72% 
Supernatant 
FS75/SGClow 10.5  0.07 21% 
FS75/SGChigh 9.8  0.045 20% 
FS75 6.8  0.11 16% 
1 2 3 4 5 6 7
300000
400000
500000
V
o
lt
Time (minutes)
Figure 4.10: HPLC analysis of D114 using 
evaporative light scattering detection (ELSD) 
revealing one distinct peak at about 2 
minutes. 
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Figure 4.11: HPLC calibration curve for 
D114 with the evaporative light scattering 
detector (ELSD). 
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liposomes (the supernatant layer) than for the resuspended lipid nanoparticles. It has been 
reported earlier that crystalline lipid nanoparticles exhibit a low drug payload capacity and 
drug expulsion into the aqueous phase may occur due to the transition into highly ordered 
lipid particles during lipid crystallization [13, 34, 41].  
 
Table 4.2: Distribution of porphyrin between resuspended crystalline nanoparticles and supernatant 
layer of FS75/SGClow, FS75/SGChigh and FS75, the percentages refer to the total amount of 
porphyrin introduced during the preparation 
 
 
As observed in the DSC, 31P-NMR spectroscopy, cryo-TEM and the HPLC analysis of 
the supernatant layer, which contains the excess emulsifier S75, this supernatant layer also 
contains a certain amount of D114 crystalline nanoparticles and this may increase the drug 
content in the liposomal layers. The low drug content of the resuspended crystalline lipid 
nanoparticles of the FS75/SGClow (26%) may be due to the filtration process after 
sonication, which led to a loss of the drug together with the triglyceride as demonstrated in 
the HPLC analysis. The highest amount of the drug in the supernatant of FS75 (70%) may 
be attributed to the highest content of S75 (3.2%) and so the highest amount of liposomes in 
this formulation. 
 
4.1.7 Particle size of D118 nanoparticles 
Figure 4.12 shows the particle size of the two formulations of D118 in the different 
physical state of the lipid. The particle size of the nanoparticles stored immediately after 
preparation at 4°C was lower than the particles that were placed in a shaker water bath at 
50°C for 8 hours followed by storage at 23°C. This indicates that the particles stored at 4°C 
may be in the -form while the particles heated to 50°C for 8 hours may be in the -form. As 
reported before [67], the changes in the polymorphic form are accompanied by increase in 
the particle size, which explains the difference in the particle size between the cold stored 
particles and the particles heated to 50°C. 
The particle size was also measured with LD-PIDS in order to determine if any large 
particles (µm size range) had formed after heating the nanoparticles to 50°C (figures 4.13 
and 4.14). µm-sized particles were not detected and no remarkable difference in the particle 
size could be observed between the different types of particles of the two formulations. 
 
 FS75/SGClow FS75/SGChigh FS75 
Resuspended nanoparticles 
(pellets) 
26%  2.4 
(0.13 mg/ml) 
35%  1.5 
(0.17 mg/ml) 
32%  1.3 
(0.16 mg/ml) 
Supernatant layer 63%  1.7 66%  2.1 70%  1.9 
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4.1.8 DSC of D118 nanoparticles 
In order to confirm the physical states of the donor D118 lipid nanoparticles and to 
determine their polymorphic form, DSC measurements were performed. Figure 4.15 (a and 
b) illustrates the DSC melting and cooling curves of D118 nanoparticles stabilized with 1.8% 
S75-3 and 0.45% SGC. The heating curve of the cold stored D118 nanoparticles displayed a 
large endotherm around 52°C which points to the presence of -polymorph (figure 4.15 (a)). 
Aging the sample at elevated temperatures (50°C for 8 hours) close to the -melting point 
transformed the particles into the -modification (figure 4.15 (b)). The presence of -
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Figure 4.12: PCS z-average mean particle size (bars) and polydispersity indices (PDI, circles) of 
D118 nanoparticles stored at 4°C immediately after preparation or at 23°C after heating to 50°C for 
8 hours (n = 3). 
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Figure 4.13: LD-PIDS particle size distribution 
of D118 nanoparticles prepared with 1.8% S75-
3 and 0.45% SGC and stored at 4°C 
immediately after preparation or at 23°C after 
heating to 50°C for 8 hours. 
Figure 4.14: LD-PIDS particle size distribution 
of D118 nanoparticles prepared with 4% PVA 
and stored at 4°C immediately after preparation 
or at 23°C after heating to 50°C for 8 hours. 
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polymorph in case of the sample stored at 4°C could be attributed to the stabilization of 
tristearin nanoparticles with an emulsifier mixture containing hydrogenated soybean 
phospholipid (with fully saturated acyl chains) [65-66]. This hydrogenated soybean 
phospholipid forms a shell of solidified phospholipid in the emulsifier monolayer surrounding 
the triglyceride core of the nanoparticles. This solidified phospholipid shell could act as a 
template for surface nucleation causing the increase in the crystallization temperature (about 
38°C) and suppresses the polymorphic transformation (figure 4.15 (a, b)).  
For tristearin nanoparticles stabilized with 4% PVA and stored at 4°C immediately after 
preparation, there was no evidence of the presence of -polymorph because there was no 
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Figure 4.15: DSC melting and cooling curves of D118 nanoparticles prepared with 1.8% S75-3 and 
0.45% SGC as stabilizers. a)- Particles stored at 4°C immediately after preparation, b)- Particles 
heated to 50°C for 8 hours and stored at 23°C. 
30 40 50 60 70 80 90
 
N
o
rm
a
li
z
e
d
 h
e
a
t 
fl
o
w
 (
m
V
/m
g
) 
e
n
d
o
Temperature (°C)  
  
First heating 
Second  heating 
Cooling 
(a) 
30 40 50 60 70 80 90
 
N
o
rm
a
li
z
e
d
 h
e
a
t 
fl
o
w
 (
m
V
/m
g
) 
e
n
d
o
Temperature (°C) 
 
 
 
First heating 
Second  heating 
Cooling 
(b) 
Figure 4.16: DSC melting and cooling curves of D118 nanoparticles prepared with 4% PVA as a 
stabilizer. a)- Particles stored at 4°C immediately after preparation, b)- Particles heated to 50°C for 
8 hours and stored at 23°C. 
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melting peak in the -polymorphic region (about 68°C). Only one endothermic peak around 
52°C, which points to the presence of -polymorph, was detected (figure 4.16 (a)).  Aging 
this sample at elevated temperatures (50°C for 8 hours) close to the -melting point 
transformed the particles into the -modification (figure 4.16 (b)). Unlike the particles 
stabilized with S75-3, which showed complete transformation into -modification by aging at 
50°C, the particles stabilized with 4% PVA did not transform completely under these 
conditions but a small fraction of the particles remained in the -form (figure 4.16 (b)). The 
nanoparticles prepared with PVA showed also a high stability of the -polymorph. One 
explanation might be that PVA causes a high viscosity or immobilization of the molecules in 
the interfacial region and therefore sterically hinders the conversion from  to  as reported 
before [67]. The crystallization temperature of the particles stabilized with 4% PVA was about 
30°C (figure 4.16) while the crystallization temperature of the particles stabilized with 1.8% 
S75-3 was about 38°C (figure 4.15), which also confirms that the stabilization of the particles 
with hydrogenated soybean phospholipid increases the crystallization temperature due to the 
templating action of the solidified phospholipid shell. 
 
4.1.9 Particle size and zeta potential of Miglyol nanoemulsions 
Five formulations of Miglyol nanoemulsions were prepared by cold homogenization 
using different ratios between S75 and EPC as stabilizers. The particle size of the five 
formulations ranged between 100 and 110 nm with a good PDI ranging from 0.11 to 0.125 
(figure 4.17). This small particle size and the low PDI were very useful to check the retention 
of these particles on the ion exchange column. Any retention of such small particles on the 
column should be caused by the interaction (ion exchange) between the negatively charged 
emulsion and the gel inside the column and not due to the blockage of the column by large 
particles. Different ratios between S75 and EPC were used in the preparation of these 
emulsions to obtain emulsions with different zeta potential. As expected, the highest negative 
surface charge (-28 mV) was obtained with the highest S75 content [74] and lowest content 
of EPC, while the lowest negative surface charge (-13.5 mV) was obtained with the lowest 
S75 and the highest EPC content (figure 4.18).  
The PCS-particle size of the Miglyol nanoemulsion, which was prepared from 5% 
Miglyol and 4% poloxamer 188, was 115 nm  0.8 with a homogenous particle distribution as 
the polydispersity index (PDI) was 0.14. No significant change in the particle size was 
observed after addition of porphyrin (z-averge: 120 nm  0.54, PDI: 0.15). The zeta potential 
of this nanoemulsion without porphyrin was –4.6 mV. This Miglyol nanoemulsion was used 
also as acceptor in the transfer experiments with the ion exchange column technique due to 
its small particle size and neutral zeta potential.  
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4.2 Characterization of the acceptor particles 
 
4.2.1 Unilamellar and multilamellar vesicles 
The acceptor vesicles (unilamellar or multilamellar) were prepared from egg 
phosphatidyl choline (EPC) and cholesterol with a molar ratio of 8:2 for EPC/cholesterol. 
EPC and cholesterol were chosen to mimic the cell membranes and other lipid 
compartments in the body and to obtain acceptor vesicles with neutral charge to be used on 
the ion exchange column [3, 56, 68]. The small unilamellar vesicles as an acceptor particles 
could be prepared from EPC only as described before [57]. Recently, liposomes were utilized 
for studying drug transfer and uptake [4]. 
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Figure 4.19: LD-PIDS particle size distributions of the acceptor MLV with a molar ratio between 
EPC/cholesterol of 8:2 measured with and without stirring. 
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Figure 4.17: PCS z-average mean particle size 
(bars) and polydispersity indices (PDI, circles) 
of Miglyol nanoemulsions prepared with 
different ratios between S75 and EPC. 
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Figure 4.18: Zeta potential of the Miglyol 
nanoemulsions prepared with different 
ratios between S75 and EPC. 
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The z-average particle size of the unilamellar vesicles from EPC and cholesterol that 
had been extruded through a 100 nm membrane filter was 151.3  1.2 nm (PDI 0.07). The 
zeta potential was –5.34  1.1 mV and thus close to neutrality. The mean particle size of the 
MLV liposomes was about 10 µm (figure 4.19). LD-PIDS of the MLV liposomes after  
4 months of storage at refrigerator temperature showed no alterations in the mean particle 
size, which indicates the stability of these particles. 
 
4.2.2 Particle size of o/w emulsion droplets 
Figure 4.20 illustrates the particle size of the acceptor o/w emulsion, which was 
prepared by Ultra-Turrax homogenization. The mean particle size was about 6 µm.  
 
4.2.3 Particle size of monoolein dispersions  
As pointed out in an earlier study, coarse glycerol monooleate/poloxamer (GMO/P407) 
dispersions can be prepared by simple mixing of the components followed by mechanical 
shaking for prolonged periods of time (12 h) [69]. Such dispersions consist of particles in the 
size range of 0.2-2 µm and a fraction of larger, visually observable particles of more than  
10 µm diameter that tend to accumulate at the surface of the dispersion. It is generally 
necessary to homogenize GMO-based dispersions in order to get rid of macroscopic particle 
contaminants and to narrow the particle size distribution. However, the attempts to prepare 
cubic phase dispersions with small particles and with narrow particle size distributions by 
high shear energy homogenization usually lead to dispersions consisting of almost only 
noncubic, vesicular structures. It was reported before [18, 81-83], that heat treatment of 
monoolein/poloxamer dispersions could be used to transform such vesicular dispersions into 
dispersions of cubic phase or to improve the cubic/non-cubic particle ratio in dispersions 
already containing particles with cubic internal structure. 
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Figure 4.20: LD-PIDS particle size distribution of the o/w acceptor emulsion. 
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Figure 4.21 illustrates LD-PIDS particle size distributions of the monoolein dispersions 
prepared with different amphiphile (monoolein + poloxamer) concentrations (5, 7, 10 and 
15%) and with 12% or 8% poloxamer (related to the total amphiphile amount) before and 
after autoclaving. After homogenization, the samples prepared with 5 and 7% amphiphile 
were translucent homogeneous dispersions with monomodal particle size distributions and 
mean sizes of about 100 nm. Heat treatment transformed these dispersions into milky fluids 
Figure 4.21: LD-PIDS particle size distributions of monoolein/poloxamer nanodispersions prepared 
with different amphiphile concentrations (monoolein + poloxamer) and with poloxamer 
concentrations of 12% and 8% (related to the total content of amphiphile) before and after 
autoclaving. 
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with a mean particle size of about 320 and 440 nm for the samples with 5 and 7% 
amphiphile, respectively.  
The dispersions prepared with 10 and 15% amphiphile (12% poloxamer) were milky 
fluids already before autoclaving and characterized by bimodal particle size distributions with 
mean sizes of about 450 and 790 nm for the dispersion with 10 and 15% amphiphile, 
respectively. After autoclaving of these dispersions, there was no change in the physical 
appearance but an increase in the particle size (0.71 and 1.2 µm for the dispersion prepared 
with 10 and 15% amphiphile, respectively) and a monomodal particle size distribution was 
obtained. These results were in agreement with earlier observations showing that an 
increase in the amphiphile concentration leads to an increase in the particle size of the 
dispersion upon autoclaving [69]. The particle sizes obtained were, however, quite small to 
be used in the flow cytometric experiments. In order to prepare cubic particles in the 
micrometer size range to be used for the transfer experiments with the flow cytometric 
method, two other dispersions were prepared from 10 and 15% amphiphile but with lower 
concentration of poloxamer (8% related to the total amphiphile amount).  
Figure 4.21 shows the particle size distributions of the dispersions prepared from 10 
and 15% amphiphile with 8% poloxamer. The dispersions were milky fluids before and after 
autoclaving. The particle size of about 0.45 and 1.2 µm for the dispersions with 10 and 15% 
amphiphile, respectively, before autoclaving increased to 0.75 and 2.05 µm after autoclaving. 
The change in particle size upon heat treatment could be attributed to the particle fusion, 
which occurred during the heat treatment process. One hypothesis is that fusion is related to 
the reduced solubility and stabilizing efficiency exhibited by poly (ethylene oxide)-based 
substances at elevated temperatures [69]. According to the results of the particle size 
analysis, the autoclaved dispersions prepared from 15% amphiphile with 12 and 8% 
poloxamer were used as acceptor particles in the flow cytometric transfer experiments (a 
particle size of 1.2 and 2.05 µm can be detected by the flow cytometer). 
 
4.2.4 Small angle diffraction measurements of monoolein dispersions 
The occurrence of corresponding small angle X-ray reflections confirmed the existence 
of cubic particles in all autoclaved dispersions for all formulations with different amphiphile 
concentrations (figure 4.22). In contrast, no reflections were observed for the nonautoclaved 
dispersions prepared with 5 and 7% amphiphile. According to earlier results [18], these 
dispersions contain predominantly vesicular particles, which do not display any small angle 
reflections. The dispersions prepared from 10 and 15% amphiphile and different 
concentrations of poloxamer (8 and 12%) displayed distinct small angle reflections already 
before autoclaving, which indicates the presence of cubic particles. In all cases, the small 
angle X-ray reflections observed were characteristic of a P-type cubic phase. 
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Figure 4.22: Small angle X-ray diffractograms of monoolein/poloxamer dispersions prepared with 
different amphiphile (monoolein and poloxamer) concentrations and with two poloxamer 
concentrations before and after autoclaving.  
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4.3 Transfer studies with the column method 
 
4.3.1 Validation of the column method 
Three validation experiments were performed to check the ability of the ion exchange 
column for the separation between the donor and acceptor particles and to determine if the 
neutral acceptor particles acquired any charge from the charged donor particles or not.  
 
4.3.1.1 Acceptor recovery with radiolabeled unilamellar vesicles 
A transfer experiment with radiolabeled acceptor liposomes was performed to 
investigate if the neutral acceptor liposomes were completely eluted from the column. Figure 
4.23 shows the percent of acceptor vesicles eluted after 2, 8 and 24 hours of mixing with the 
donor particles of FS75/SGClow, FS75/SGChigh and FS75 (original nanoparticles before 
ultracentrifugation and resuspended nanoparticles after ultracentrifugation). The results show 
that with pre-equilibrated columns, 93-97% of the neutral acceptor vesicles were recovered in 
the eluate at all time points up to 24 hours. There were no differences in the elution of 
acceptor liposomes incubated with the donor before or after ultracentrifugation. The very low 
amount of the neutral acceptor vesicles retained on the column (3-7%) may be referred to a 
small amount of fusion, which may have occurred between the neutral vesicles and donors 
during incubation [56].The retention of the acceptor liposomes on the column was thus very 
low and this might indicate that there was no charge transfer from the different charged 
donors to the neutral acceptor vesicles. For more confirmation of this assumption, a second 
validation experiment was performed. 
 
 
Figure 4.23: Percentage of radiolabeled acceptor liposomes eluted from the column after incubation 
with the donor for different time intervals (n = 3). 
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4.3.1.2 Charge transfer from the donor to the acceptor 
In order to confirm that there was no charge transfer from the donor to the neutral 
acceptor particles, mixtures between the crystalline nanoparticles of FS75/SGChigh (original 
nanoparticles or resuspended nanoparticles) and neutral liposomes were separated by 
ultracentrifugation. Figure 4.24 (a and b) shows the zeta potential distribution curves of the 
mixture between the donor and acceptor after separation by ultracentrifugation. There was 
only one neutral peak observed in the supernatant layer of the mixture between the 
resuspended nanoparticles and the neutral liposomes (figure 4.24 (a) left panel). In case of 
the supernatant layer of the mixture between the original nanoparticles and the neutral 
liposomes, it could be observed that there were 2 peaks, one major peak of the neutral 
acceptor liposomes (-4 mV) and a minor peak of the unilamellar vesicles from the excess 
S75 (-45 mV) (figure 4.24 (b) left panel). From the zeta potential distributions of the two 
supernatant layers it could be concluded that there was no effect of the charged donor 
particles on the neutral liposomes or by other words there was no charge acquired by the 
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Figure 4.24: Zeta potential distribution of the mixture between the donor and acceptor particles after 
separation by ultracentrifugation at 35000 rpm for 1 hour; a) mixture between the resuspended 
crystalline lipid nanoparticles of FS75/SGChigh and the neutral acceptor liposomes; b) mixture 
between the original crystalline lipid nanoparticles of FS75/SGChigh and the neutral acceptor 
liposomes; supernatant layer (left panel); crystalline nanoparticles (right panel). 
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neutral acceptor liposomes from the charged donor. The small peak at neutral zeta potential 
in the curves of the pellets (figure 4.24 a and b (right panel)) may be attributed to the 
presence of a small amount of the neutral acceptor liposomes with the crystalline lipid 
nanoparticles. 
 
4.3.1.3 Elution of the donor particles 
Insufficient retention of the donor particles on the column would disturb the 
experiments. To check that the donor nanoparticles were completely retained on the column, 
10 µl of the original samples (before ultracentrifugation), resuspended crystalline particles 
and resuspended liquid particles (the FS75/SGClow, FS75/SGChigh and FS75) were added 
to the column. After that, the drug concentration in the eluent was analysed. Less than 1% of 
the different donors were eluted from the column (table 4.3). These results indicate the good 
retention property of the DEAE-Sepharose column for the donor particles prepared with S75 
due to their negative zeta potential (table 4.3). The same experiment was performed on the 
Fpoloxamer/DCP nanoparticles where more than 90% of the nanoparticles were eluted from 
the column (table 4.3). The low charge of these particles (zeta potential -14 mV) obviously 
does not allow their retention by DEAE-Sepharose. 
 
Table 4.3: Percentage of the different donor particles eluted from the column 
Formula Zeta potential (mV) 
Donor eluted from the 
column (%) 
Original samples 
FS75/SGClow -58  1.2 0.85  0.042 
FS75/SGChigh  -62.5  1.2 0.53  0.033 
FS75 -47  1.3 0.68  0.063 
Fpoloxamer/DCP -14  1.5 92.2  1.12 
Resuspended crystalline 
nanoparticles (pellets) 
FS75/SGClow -56  1.3 0.45  0.021 
FS75/SGChigh  -55  1.4 0.4  0.032 
FS75 -46  0.8 0.61  0.014 
Resuspended liquid 
nanoparticles (prepared by 
melting the crystalline ones) 
FS75/SGClow  0.52  0.025 
FS75/SGChigh   0.43  0.027 
FS75  0.51  0.042 
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Table 4.4: Elution of the Miglyol nanoemulsions with different zeta potential from the ion exchange 
column 
 
4.3.2 Determination of the suitable zeta potential range for the column method 
As seen from the previous section, the zeta potential had a great effect on the retention 
of the donor particles on the ion exchange column. According to this effect, it was important 
to determine the suitable zeta potential range for the donor particles to be used with the 
column method. To prepare nanoemulsions with different zeta potential, different 
concentrations of S75 and EPC were used. These experiments were performed on 
nanoemulsions and not the crystalline nanoparticles because nanoemulsions are stable with 
these emulsifier mixtures (S75 and EPC) while the crystalline nanoparticles may not stable 
with these emulsifier mixtures [39]. Table 4.4 illustrates the elution of emulsions with different 
zeta potential from the column. As expected, the nanoemulsion MigS75/EPC1 with the 
highest negative charge (-28 mV) shows the lowest percentage of elution from the column 
(1.28%) while the nanoemulsion MigS75/EPC5 with the lowest negative charge (-13.5 mV) 
shows the highest percentage of elution (50%). From these results it could be concluded that 
the emulsion or a donor with a zeta potential of –25 mV and higher can be used for the 
column method. Particles with a zeta potential of –20 mV and lower can not be used in the 
transfer experiments employing the column method for the separation between the neutral 
acceptor and the donor particles because a large fraction of the donor particles will be eluted.  
 
4.3.3 Transfer of the different drug models to the acceptor unilamellar vesicles 
The transfer experiments to the acceptor unilamellar vesicles were performed with the 
nanoparticle formulations FS75/SGClow, FS75/SGChigh and FS75 only because 
Fpoloxamer/DCP had a low zeta potential and was thus insufficiently retained on the column. 
Figure 4.25 (a, b and c) shows the porphyrin transfer from the crystalline and liquid donor 
particles of FS75/SGClow, FS75/SGChigh and FS75. The three formulations showed a rapid 
initial drug transfer. At a molar ratio of 1:25, 14%, 15% and 15.5% of porphyrin had been 
Sample  Zeta potential (mV) 
Nanoemulsion eluted from the ion exchange 
column (%) 
MigS75/EPC1  -28 1.28  1.02 
MigS75/EPC2 -25 3  1.05 
MigS75/EPC3  -20 18  3.6 
MigS75/EPC4  -17 35  4.8 
MigS75/EPC5  -13 50  6.3 
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transferred from the crystalline donors of FS75/SGClow, FS75/SGChigh and FS75, 
respectively, after 2 minutes (first time point of measurements). For the same formulations at 
a molar ratio of 1:100, the initial drug transfer (after 2 minutes) was 33.5%, 35% and 33% for 
FS75/SGClow, FS75/SGChigh and FS75. A plateau value was reached after about 40 
minutes in all cases with similar equilibrium values (about 40 and 80% with molar ratios of 
1:25 and 1:100, respectively) for the three formulations (table 4.5). This observation indicates 
that the time course of drug transfer did not depend on the lipid ratio between the donor and 
acceptor and that the lipid ratio only affects the amount of drug transfer (table 4.5).  
The final amount of drug transferred from the three formulations at both donor: 
acceptor molar ratios was much lower than the expected values (theoretical values). 
Assuming an equal porphyrin distribution between the donor and acceptor, about 99% of the 
porphyrin was expected in the acceptor unilamellar vesicles at a molar ratio of 1:100 between 
the donor and acceptor and about 96% of the porphyrin was expected in the acceptor 
particles used at a molar ratio of 1:25.   
These low equilibrium values might be attributed to the localization of the drug at the 
interface of the acceptor liposomes (porphyrin did not entrapped in the vesicles bilayer) [84], 
which means that after saturation of this interface the transfer stopped at low values. 
Additionally, the acceptor unilamellar vesicles were prepared from EPC with the addition of 
cholesterol, which increases the rigidity of the bilayer [85] and occupies a part of the 
accessible outer surface and so decreased the amount of drug transfer to the acceptor 
liposomes. 
Increasing the acceptor to donor ratio from 1:25 to 1:100 led to an increase in the final 
percent of drug transferred (table 4.5, figure 4.25) and this may be attributed to the increase 
in the number of the acceptor particles relative to the donor particles. This increase in the 
number of the acceptor particles will lead to an increase in the accessible surface available 
for drug transfer. 
There were no or only slight differences in the transfer between the crystalline and 
liquid donor for the three formulations at low donor: acceptor ratios (1:25) (figure 4.25). A 
slightly higher drug transfer from the crystalline donor particles compared to the liquid 
particles was observed at the higher donor: acceptor ratio (1:100) (figure 4.25). This higher 
drug transfer from crystalline compared to liquid donor might be attributed to the formation of 
highly ordered particles in the  modification upon crystallization, which leaves little space for 
the drug molecules, and so leads to the expulsion of drug to the surface of the crystalline 
particles [34, 41, 86-87].  
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Table 4.5: Results of the transfer studies with porphyrin to the acceptor unilamellar vesicles obtained 
by the column method assuming transfer kinetics according to equation [1] 
 
All kinetics values were obtained from the fitted curves and the equilibrium time was determined by 
calculating the time at which 99% of the plateau was reached. The same procedure was performed 
with all transfer data shown in the following tables. 
 
One of the important factors, which affect the drug transfer, is the total lipid 
concentration of both the acceptor and donor in the transfer mixture [6]. To study the effect of 
the total lipid concentration on porphyrin transfer, the transfer experiment from 
FS75/SGChigh (resuspended crystalline nanoparticles) to the acceptor unilamellar vesicles 
was carried out with different lipid concentrations in the transfer mixture and with the two 
molar ratios 1:25 and 1:100. 
 
 
Donor 
Molar 
ratio 
Total lipid 
concentration 
(mg/ml) 
Transfer rate 
constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium 
time 
(minutes) 
FS75/SGClow
 
 
(liquid) 
1:25 18 0.1  0.007 38.5  1.6 40 
1:100 68 0.11  0.011 76  2.2 38 
FS75/SGClow
 
 
(crystalline) 
1:25 18 0.1  0.006 40  1.9 38 
1:100 68 0.1  0.01 79  2.7 37 
FS75/SGChigh
 
(liquid) 
1:25 18 0.1  0.007 41  2.2 38 
1:100 68 0.09  0.008 78  2.4 43 
FS75/SGChigh
 
 
(crystalline) 
1:25 18 0.095  0.005 43  1.5 42 
1:100 68 0.1  0.009 80  1.3 39 
FS75 (liquid) 
1:25 18 0.1  0.009 41  1.9 38 
1:100 68 0.09  0.011 76  0.9 42 
FS75 (crystalline) 
1:25 18 0.11  0.008 40  2.1 39 
1:100 68 0.1  0.01 79.5  2.5 39 
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By decreasing the total lipid concentration from 50 mg/ml to 5 mg/ml at a molar ratio of 
1:100, the transfer rate decreased as expected (figure 4.26, table 4.6). The final amount 
transferred was about 80, 76 and 72.5% with a transfer rate constant of 0.1, 0.09 and 0.032 
min-1 for the lipid concentration 68, 50 and 5 mg/ml, respectively. The steady state was 
reached after 39 and 45 minutes in the case of lipid concentrations of 68 and 50 mg/ml, 
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Figure 4.25: Percentage of porphyrin transferred from the crystalline and liquid donor particles to 
the acceptor unilamellar vesicles with molar ratios of 1:25 and 1:100, a) FS75/SGClow, b) 
FS75/SGChigh, c) FS75, measurements results (left panel), fitted curves (right panel), n = 3. 
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respectively, while at a lipid concentration of 5 mg/ml the steady state was reached only after 
95 minutes (table 4.6).  Transfer occurs either by one of the following two mechanisms or by 
both mechanisms at the same time [88]. The first mechanism is the collision, which needs a 
direct contact of donor and acceptor particles in the transfer mixture and this mechanism has 
been described between colloidal carrier particles and cells [88-89]. The second one 
depends on the diffusion of the drug through the aqueous phase [90-91]. The increase in the 
drug transfer rate by increasing the total lipid concentration might be related to the 
decreasing distance between the donor and acceptor particles inside the transfer mixture. 
The smaller distance between the donor and acceptor particles at higher lipid concentrations 
may facilitate the drug transfer from the donor to the acceptor particles by one of the two 
mechanisms (collision or diffusion) and thus increase the rate of drug transfer. The amount of 
drug transferred in the equilibrium did not depend much on the lipid concentration. This is 
expected since the transfer experiments were done with the same molar ratio between the 
donor and acceptor (1:100). With a molar ratio of 1:25, the final percent of drug transferred 
was about 43 and 55% with lipid concentrations of 18 and 50 mg/ml, respectively.  
Figure 4.26: Porphyrin transfer (column method) from the resuspended crystalline donor 
nanoparticles of FS75/SGChigh to the acceptor unilamellar vesicles with different lipid 
concentrations, a) lipid molar ratio 1:100, b) lipid molar ratio 1:25, measurement results (left panel), 
fitted curves (right panel), n = 3. 
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Table 4.6: Results of the transfer studies with porphyrin from the crystalline resuspended 
nanoparticles of FS75/SGChigh to the acceptor unilamellar vesicles obtained by the column method 
assuming transfer kinetics according to equation [1] 
 
 
The transfer rate constant was nearly the same with both lipid concentrations (about 
0.1 min-1) leading to an equilibrium time of about 42 minutes (table 4.6). The transfer rate 
constant was thus nearly the same with the different molar ratios and the different lipid 
concentrations except with a lipid concentration of 5 mg/ml which had a lower transfer rate 
than the other lipid concentrations (table 4.6). These results were in agreements with 
previous observations [6], which showed that the transfer rate of Nile red from D114 
nanoparticles to acceptor o/w emulsion droplets decreased after the dilution (decreasing the 
total lipid concentration) of the transfer mixture. 
 The lipophilicity of the drug model used is considered as one of the most important 
factors, which affect the drug transfer [6]. For that reason, the transfer of Nile red (logP 3.65) 
[6], which is less lipophilic than porphyrin (logP 9) [6], and Di , which is more lipophilic than 
porphyrin (logP 20) [64], to the acceptor unilamellar vesicles was measured for comparison. 
The transfer of Nile red was very rapid and seemed to be completed already after 1 minute 
(figure 4.27). Assuming an equal distribution of Nile red between the donor and acceptor, 
about 99% of the Nile red would be expected in the acceptor particles at equilibrium. The 
drug transfer at equilibrium corresponded to the expected value, which indicates that all of 
the Nile red must have transferred from the donor to the acceptor particles. Large differences 
were thus observed between the transfer of porphyrin and Nile red. Porphyrin transfer 
reached equilibrium values lower than expected with a molar ratio of 1:100 while Nile red 
transfer reached the expected equilibrium value (table 4.7). By comparing the transfer of Nile 
red and porphyrin to the acceptor unilamellar vesicles, it may be assumed that porphyrin 
transfer occurred to the outer surface of the acceptor particles and that porphyrin has low or 
Molar ratio 
Total lipid 
concentration (mg/ml) 
Transfer rate constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium time 
(minutes) 
1:25 
18 0.095  0.005 43  1.5 42 
50 0.09  0.002 55  1.1 42 
1:100 
5 0.032  0.004 72.5  1.5 95 
50 0.09  0.003 76  1.6 45 
68 0.1  0.009 80  1.3 39 
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no ability to get inside the inner interface layers of the acceptor particles.  However, Nile red 
has the ability to get inside the inner interface of the acceptor particles due to its lower 
lipophilicity and consequently its higher diffusion than porphyrin. Contrary to Nile red transfer, 
the Di  transfer to the acceptor unilamellar vesicles was very slow. The amount of Di  
transferred after 5 days was about 3.8% (figure 4.28) with a very low transfer rate constant 
(0.4 day-1) (table 4.7). This very slow transfer rate to the acceptor unilamellar vesicles was 
nearly the same as in previous results of Di  transfer to an acceptor emulsion [6]. This very 
slow Di  transfer to the acceptor unilamellar vesicles could be attributed to the very high 
lipophilicity of Di  (due to its long alkyl chains), which decreases the diffusion of the drug 
molecule through the aqueous phase to a very high extent.  
 
 
Figure 4.27: Nile red transfer from the resuspended crystalline nanoparticles of FS75/SGChigh to 
the acceptor unilamellar vesicles with a molar ratio 1:100, measurement results (left), fitted curve 
(right), n = 3. 
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Figure 4.28: Di  transfer from the resuspended crystalline nanoparticles of FS75/SGChigh to the 
acceptor unilamellar vesicles with a molar ratio 1:100, measurement results (left), fitted curve (right), 
n = 3. 
0 1 2 3 4 5
0
2
4
6
8
95
100
%
 D
iI
 t
ra
n
s
fe
rr
e
d
Time (days)
0 1 2 3 4 5
0
2
4
6
8
95
100
Time (days)
%
 D
iI
 t
ra
n
s
fe
rr
e
d
Chapter 4: Results and discussion 
 
  61 
Table 4.7: Results of the transfer studies for the different drug models to the acceptor unilamellar 
vesicles with a donor: acceptor molar ratio of 1:100 and a total lipid concentration of 50 mg/ml 
obtained by the column method assuming transfer kinetics according to equation [1] 
 
4.3.4 Porphyrin transfer to monoolein dispersions and a Miglyol nanoemulsion 
In order to investigate the effect of the acceptor lipid composition and structure on the 
transfer of porphyrin, the transfer of porphyrin to acceptor monoolein dispersions and a 
Miglyol nanoemulsion was studied. As a first step the suitability of monoolein/poloxamer 
nanodispersions (vesicular and cubic particles) and the Miglyol nanoemulsion as acceptors 
for transfer experiments with the column method was tested. Drug loaded samples were 
prepared to measure the recovery of the acceptor from the column. The fraction of the 
different acceptor particles that was retained on the ion exchange column was always less 
than 2% (table 4.8). These results indicate the suitability of these acceptor nanodispersions 
for transfer experiments with the ion exchange column. Although the size of the monoolein 
cubic particles was large in comparison with the monoolein vesicles and the Miglyol 
nanoemulsion, their retention on the column was comparable with that of monoolein vesicles 
and the Miglyol nanoemulsion. With the three types of alternative acceptor particles the 
transfer experiments were carried out from the crystalline resuspended nanoparticles of 
FS75/SGChigh. The drug transfer to the acceptor monoolein dispersions was very rapid and 
equilibrated after about 1.5 minutes (figure 4.29, table 4.9). The equilibrium values for both 
acceptors (vesicles and cubic particles) were close to the expected value of the equal 
distribution (more than 90%) (table 4.9). 
 
Table 4.8: Retention of the acceptor Miglyol nanoemulsion and the acceptor monoolein/poloxamer 
nanodispersions on the ion exchange column, data were obtained with porphyrin loaded samples 
Donor 
Transfer rate constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium time 
(minutes) 
FS75/SGChigh (porphyrin) 0.09  0.003 76  1.6 45 
FS75/SGChigh (Nile red) 3.6  1.34 100  2.6 1 
FS75/SGChigh (Di ) 
2.7 * 10
-4
 ± 0.27 * 10
-4
  
(0.4 day
-1
) 
3.8 ± 0.14 7200 (5 days) 
Formula Fraction retained (%) 
Monoolein vesicles (5% amphiphile, 12% poloxamer, 95 nm/ –4.3 mV) 1.3  0.25 
Monoolein cubic particles (5% amphiphile, 12% poloxamer, 310 nm/  
–3.5 mV) 
1  0.12 
Miglyol nanoemulsion (5% Miglyol, 4% poloxamer 188, 113 nm/  
–4.6 mV) 
1.8  0.42 
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The course of drug transfer from the donor particles to the two different monoolein 
dispersions was nearly the same (figure 4.29). The transfer rate constant and the final 
percent of drug transfer were very high in comparison with the “conventional” acceptor 
particles (unilamellar vesicles) (table 4.9). With the same molar ratio (1:25) and the same 
lipid concentration (about 50 mg/ml), the transfer rate constant and the final percent 
transferred from the resuspended crystalline lipid nanoparticles of FS75/SGChigh to the 
acceptor unilamellar vesicles were 0.09 min-1 and 55%, respectively, while with the acceptor 
monoolein/poloxamer vesicles they were 2.62 min-1 and 93%, respectively. The equilibration 
time was about 42 minutes with the acceptor unilamellar vesicles while it was only about  
1.5 minutes with the acceptor monoolein/poloxamer nanodispersions (table 4.9). 
These differences between the two acceptors may be attributed to the difference in the 
lipid composition of the two types of acceptor particles. In the case of monoolein, the 
hydrophilic lipophilic balance (HLB) is about 3.8 [92] while in the case of the acceptor 
unilamellar vesicles the HLB of EPC is about 9 [93-94]. This difference in the HLB between 
the two lipids indicates that monoolein is more hydrophobic than EPC. Monoolein has a small 
hydrophilic head group which may allow the penetration of the drug to the water interface 
inside the vesicles (high lipid water interface in which the drug can distribute). In other words, 
the high hydrophobicity of monoolein in comparison with EPC facilitates the diffusion of the 
drug molecules to the water interface inside the vesicles. While the HLB of EPC indicates 
that EPC has a relatively large hydrophilic head group which may either hinder the 
penetration or decrease the diffusion rate of porphyrin to the interface inside the vesicles. 
These results are in agreement with previous observations [95], which indicate that cubic 
particles should be quite useful for a rapid uptake because they can rapidly absorb pollutants 
(e.g., for water treatment or cosmetic skin protection) and retain an amount determined by 
the solute partition coefficient.  
Figure 4.29: Porphyrin transfer (column method) from the resuspended crystalline donor particles of 
FS75/SGChigh to the acceptor monoolein dispersions prepared from 5% amphiphile and 12% 
poloxamer without autoclaving (vesicles) or with autoclaving (cubic particles) with a donor: acceptor 
molar ratio of 1:25, measurement results (left), fitted curve (right), n = 3. 
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Table 4.9: Results of the transfer studies with porphyrin from the crystalline resuspended 
nanoparticles of FS75/SGChigh to different acceptors obtained by the column method assuming 
transfer kinetics according to equation [1] 
 
* Data from table 4.6 
This rapid uptake of the pollutants by the monoolein cubic particles could be attributed to the 
sponge like structure of the cubic monoolein particles. This sponge like structure may lead to 
the high transfer rate and the complete drug transfer that was observed with the acceptor 
monoolein cubic particles. In addition to the low HLB value of monoolein and the sponge like 
structure of the cubic phase, the cubic bicontinuous phase has a unique structure where the 
monoolein bilayer (internal structure) is extending in three dimensions, with a high specific 
bilayer/water interfacial area (500-600 m2/g lipid) [17]. As mentioned before [84], the 
interfacial area (lipid/water interface) plays an important role in the transfer of porphyrin to the 
different acceptor particles. This unique structure of the cubic particles facilitates the mobility 
of the drug molecules within the bilayer. All of these factors make the cubic phase a suitable 
candidate for receiving the porphyrin molecules from the donor particles. On the other hand, 
presence of cholesterol in the acceptor unilamellar vesicles increases the rigidity of the 
membrane surface and occupies a part from this surface and thus hinders the localization of 
the drug at the outer interface and decreases the rate of porphyrin diffusion to the interface 
inside the vesicles. 
Figure 4.30 illustrates the transfer of porphyrin to the acceptor Miglyol nanoemulsion. 
Also with this acceptor, the drug transfer was very rapid (K = 1 min-1) and the equilibrium 
value (85%) was obtained after 4 minutes (figure 4.30, table 4.9). As observed with the 
acceptor unilamellar vesicles, the final fraction of porphyrin transferred to the acceptor 
Miglyol nanoemulsion was lower than the expected value (99%) (table 4.9). The transfer rate 
to the acceptor Miglyol nanoemulsion was higher than to the acceptor unilamellar vesicles 
while the equilibrium amount was nearly the same. These results could be attributed to the 
difference in the lipid composition between the two acceptor particles. The transfer from the 
donor trimyristin (medium chain triglyceride) to the acceptor particles, which were also 
prepared from medium chain triglyceride (Miglyol), may be the reason for the difference 
between the two acceptors. 
Acceptor 
Molar 
ratio 
Total lipid 
concentration 
(mg/ml) 
Transfer rate 
constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium time 
(minutes) 
Monoolein vesicles 1:25 48 2.62  0.16 93.3  1.5 1.5 
Monoolein cubic 
particles 
1:25 48 2.5  0.27 91.5  1 1.5 
Unilamellar 
vesicles* 
1:25 50 0.09  0.002 55  1.1 42 
Miglyol 
nanoemulsion 
1:100 50 1.08  0.091 85  2.1 4 
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4.3.5 Porphyrin affinity to monoolein dispersions and to unilamellar vesicles  
Porphyrin was transferred to the different acceptor monoolein dispersions very rapidly 
and complete drug transfer (until equilibrium) was obtained with these acceptor particles. To 
explore the background of this phenomenon in more detail, especially in comparison with 
unilamellar phospholipid vesicles as acceptor particles, time dependent solubilization studies 
were carried out with the porphyrin. Already by visual observation (figure 4.31) the high 
affinity of porphyrin to the acceptor monoolein dispersions in the form of vesicles or cubic 
particles was obvious. The uptake of the porphyrin by the monoolein particles was much 
faster than by the unilamellar liposomes. It also reached a distinctly higher value within the 
time frame of the experiment as evident from the spectroscopic investigations (figure 4.31). 
With the monoolein acceptor particles, the saturation with porphyrin had almost been 
reached already after 5 minutes whereas uptake continued over many hours with the 
liposomes (figure 4.32). Obviously, the affinity of porphyrin to the acceptor monoolein 
dispersions is much higher than that to the phospholipid vesicles. Although the monoolein 
vesicles and monoolein cubic particles contain the same amount of porphyrin the monoolein 
vesicles appeared much darker than the cubic particles. This could be attributed to the 
difference in the appearance between the drug free monoolein vesicles and the monoolein 
cubic particles. The monoolein vesicles are translucent while the cubic particles have a milky 
appearance. 
 
4.3.6 Transfer of DiI to the acceptor monoolein cubic particles 
The transfer of porphyrin to the acceptor monoolein dispersions (vesicular and cubic 
nanoparticles) was characterized by a very rapid drug transfer and the equilibrium values 
were the same as the expected values (complete drug transfer). To further evaluate the 
suitability of monoolein dispersions as acceptor for very lipophilic substances, Di , which is a 
Figure 4.30: Porphyrin transfer (column method) from the resuspended crystalline donor particles of 
FS75/SGChigh to the acceptor Miglyol nanoemulsion prepared from 5% Miglyol and 4% poloxamer 
with a donor: acceptor molar ratio of 1:25, measurement results (left), fitted curve (right), n = 3. 
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very lipophilic dye (more lipophilic than porphyrin), was used as a drug model to measure the 
drug transfer to the acceptor monoolein dispersions. As reported before [6], the transfer rate 
of Di  from lipid nanoparticles (2% D114 nanoparticles stabilized with 1.6% poloxamer 188) 
to large acceptor emulsion droplets (5% Miglyol 812 droplets stabilized with 3% polyvinyl 
alcohol, 8 µm) was very low. The amount of dye transferred in equilibrium was at most about 
7%, which was far away from the calculated equilibrium value (  96%). The transfer of Di  to 
Figure 4.31: Optical appearance of dispersions of unilamellar (PL) vesicles, monoolein cubic 
particles and monoolein (Mo) vesicles at different time points after mixing with excess porphyrin 
powder. 
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Figure 4.32: Amount of porphyrin incorporated with the different acceptors at different time points 
after mixing the acceptors with the excess porphyrin powder.  
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acceptor unilamellar vesicles was also very slow and only a very small fraction of the dye 
was transferred. Therefore, the transfer of Di  from FS75/SGChigh to the acceptor monoolein 
cubic particles was measured and compared to the previous results with the different 
acceptors and also compared with the transfer of porphyrin. In contrast to the transfer to the 
acceptor emulsion and unilamellar vesicles, most of Di  was transferred after 40 minutes of 
incubation with the acceptor monoolein cubic particles (figure 4.33). The amount transferred 
in equilibrium was about 82% and 67% with donor:acceptor molar ratios of 1:25 and 1:100, 
respectively (table 4.10). These equilibrium values were reached after about 40 minutes with 
the different molar ratios. The transfer of Di  was characterized by a very rapid initial dye 
transfer (burst release). More than 30% had been transferred after 2 minutes with a molar 
ratio of 1:25 and with a molar ratio of 1:100 more than 40% had been transferred after  
2 minutes. The transfer rate constant was about 0.09 min-1 with no difference between the 
two molar ratios (table 4.10). The transfer rate constant to the acceptor monoolein cubic 
particles was much higher than the transfer rate constant to the acceptor emulsion (about 
0.04 day-1) [6]. These differences in the transfer of Di  between the two acceptors could be 
attributed to the differences in the particle size and the available lipid/water interfacial area 
between the two acceptors. The particle size of the cubic particles was 320 nm while the 
particle size of the acceptor emulsion droplets was 8 µm. The transfer rate and the 
transferred amount of Di  to the unilamellar vesicles were much lower than those observed 
with the cubic particles (table 4.10). These differences might be related to the difference in 
the lipophilicity between the two acceptors where monoolein cubic particles are more 
lipophilic than EPC unilamellar vesicles, which facilitate the transfer of Di  to the cubic 
particles. Although the transfer rate and transferred amount of Di  to the acceptor monoolein 
cubic particles was much higher in comparison to the acceptor emulsion the transfer was not 
complete (equilibrium values were less than the expected values) and the transfer rate 
constant was smaller than the transfer rate constant of porphyrin (table 4.10). These 
differences in the transfer rate constant and the transferred amount between porphyrin and 
Di  can be attributed to the difference in the lipophilicity of the two dyes. The results of Di  
and porphyrin transfer to the acceptor monoolein dispersions indicate a high affinity of the 
different lipophilic dyes to the acceptor monoolein, which may be attributed to the high 
lipophilicity and the high bilayer/water interfacial area of the monoolein dispersions. This high 
interfacial area and lipophilicity make the monoolein dispersions a good candidate for the 
incorporation of the different lipophilic dyes inside the acceptor particles. 
 
4.3.7 Practical considerations of the column method 
To measure the transfer by the column method, it was important before each 
experiment to prepare the gel for filling the columns (about 30 columns for each experiment) 
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and after each experiment these columns had to be carefully cleaned and dried. 
Furthermore, since each column needs 1 ml of gel the method is not inexpensive. About  
1 minute was needed to separate the donor and acceptor particles, which means that the 
time resolution of the method is not below 1 minute. Moreover, one of the two populations 
(donor or acceptor) should be charged and both should have a small particle size. This 
makes this method tedious and not easy to handle. 
 
Table 4.10: Results of transfer studies of porphyrin and Di  obtained by the column method assuming 
transfer kinetics according to equation [1] 
 
4.4 Transfer studies with the centrifugation method 
Another transfer method, which depends on centrifugation to separate the donor and 
acceptor particles, was used to measure the transfer kinetics of the three drug models. This 
method was chosen because it does not require the use of charged donor particles as with 
the ion exchange column technique. This advantage of the centrifugation method over the 
ion exchange made it possible to measure the transfer from Fpoloxamer/DCP, which had a 
low charge and cannot be measured by the column method. 
Donor Acceptor 
Molar 
ratio 
Total lipid 
concentration 
(mg/ml) 
Transfer rate 
constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium 
time 
(minutes) 
FS75/SGChigh 
(Di ) 
Cubic 
particles 
1:25 48 0.093  0.002 67.2  0.3 40 
1:100 45 0.098  0.003 81.8  0.26 40 
Unilamellar 
vesicles 
1:100 50 
2.7 * 10
-4
 ± 
0.27 * 10
-4
 
3.8 ± 0.14 
7200  
(5 days) 
FS75/SGChigh 
(porphyrin) 
Cubic 
particles 
1:25 48 2.5  0.27 91.5  1 1.5 
Figure 4.33: Di  transfer (column method) from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor cubic particles (4.4% monoolein, 0.6% poloxamer, 320 nm), 
measurement results (left), fitted curve (right), n = 3. 
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4.4.1 Transfer of porphyrin to the different acceptors (MLV and emulsion) 
Porphyrin transfer from the liquid lipid nanoparticles of FS75/SGClow, FS75/SGChigh, 
FS75 and Fpoloxamer/DCP to the acceptor MLV, which had a mean particle size of 10 µm, 
was investigated. The donor and acceptor particles were separated by centrifugation where 
the donor will appear in the supernatant layer and the acceptor MLV will be separated as 
pellets. To investigate the effect of the molar ratio between the donor and acceptor on the 
initial amount of drug transferred, amount of drug transferred in equilibrium and the rate of 
drug transfer, the transfer experiments were carried out with different molar ratios (1:25, 1:50 
and 1:100). For a molar ratio of 1:100, the amount of drug transferred after 0.5 hour was 27, 
23, 20 and 28% for FS75/SGClow, FS75/SGChigh, FS75 and Fpoloxamer/DCP, respectively 
(figure 4.34). The transfer of porphyrin to the acceptor MLV was slow and the equilibrium was 
obtained after several hours. The steady state concentration was reached after about  
12 hours with all formulations at a molar ratio of 1:25 while the equilibrium was obtained after 
about 11 and 10 hours at molar ratios of 1:50 and 1:100, respectively (table 4.11). The 
transfer rate constant ranged from 0.005 and 0.0068 min-1 for the four formulations with the 
different molar ratios (1:25, 1:50 and 1:100). Obviously, the different molar ratios affect only 
the final fraction of drug transferred and have no significant effect on the transfer rate 
constant. There were virtually no differences in the final percent of drug transferred and the 
transfer rate constant between the four formulations, which were prepared with different 
emulsifier concentrations. With the centrifugation method, it was also possible to determine 
the fraction of porphyrin that was retained in the nanoparticles at different time points. The 
recovery of porphyrin (total of percentage transferred and retained) ranged between 95 and 
103%, which was a good results. Porphyrin transfer from resuspended crystalline 
nanoparticles of FS75/SGChigh and the original crystalline nanoparticles of Fpoloxamer/DCP 
to the acceptor o/w emulsion, which had a mean particle size of 6 µm, was measured after 
separating the donor and acceptor by ultracentrifugation. Here, the crystalline donor will be 
separated as pellet and the acceptor emulsion will appear in the supernatant as a creamy 
emulsion layer. Contrary to the acceptor MLV, the drug transfer to the acceptor emulsion was 
very rapid and equilibrium was obtained after about 3 minutes with both donor formulations 
(figure 4.35, table 4.11). After 30 seconds, the drug transfer was about 15% for both 
formulations and at equilibrium about 33% had been transferred from both formulations. 
Although the final percent of drug transfer to the acceptor emulsion was nearly the same as 
with the acceptor MLV (at the same donor: acceptor molar ratio of 1:25), the transfer rate 
constant with the acceptor emulsion was much higher than with the acceptor MLV (table 
4.11). The main reason for this large difference in the drug transfer rate between the two 
acceptors can be attributed to the difference in the composition and particle size of the two 
acceptors. The acceptor MLV particles were composed of multilayers and had a mean 
Chapter 4: Results and discussion 
 
  69 
particle size of about 11 µm. In contrast, the acceptor emulsion with a mean particle size of  
6 µm was composed of a single droplet (no layers). This difference in the particle size means 
that higher number of acceptor emulsion particles was present in the transfer mixture in 
comparison with the acceptor MLV. Thus, a higher rate of porphyrin transfer to the acceptor 
emulsion was observed in comparison with the acceptor MLV. Additionally, the acceptor MLV 
was prepared from EPC with cholesterol, which increases the rigidity of the bilayer and thus 
decreases the rate of porphyrin transfer from layer to layer within the MLV multilayer. With 
both acceptors, the final percent of drug transferred was much lower than the expected 
Figure 4.34: Porphyrin transfer (centrifugation method) from the resuspended liquid lipid 
nanoparticles of the four D114 formulations to the acceptor MLV; porphyrin transferred (left panel), 
fitted curves (right panel), n = 3. 
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values (table 4.11). The maximum amount of porphyrin transferred was between 35-70% for 
the three donor:acceptor ratios. The reason for this low equilibrium values might be the 
localization of porphyrin at the interface of the particles. Due to the limited size of the large 
acceptor particles, saturation might occur and thus probably the transfer stopped at a low 
level. In an attempt to check the effect of the stabilizer PVA on the transfer of the porphyrin, 
3% PVA was added to the MLV acceptor (the same concentration that was used in the 
preparation of the acceptor emulsion). There was no difference in the rate and amount of 
porphyrin transfer to the acceptor MLV with and without the presence of PVA. The initial drug 
transfer after 0.5 hour was 22% and 19% for the acceptor MLV with and without PVA, 
respectively. Equilibrium was obtained after about 11 and 10 hours with an equilibrium 
amount of 60% and 65% for the acceptor MLV with and without PVA, respectively (figure 
4.36, table 4.11). These results indicate that PVA has no effect on the transfer of porphyrin to 
the acceptor MLV. 
Figure 4.36: Porphyrin transfer (centrifugation method) from the resuspended liquid lipid 
nanoparticles of Fpoloxamer/DCP to the acceptor MLV with and without the presence of PVA, molar 
ratio 1:100; measurement results (left), fitted curve (right), n = 3. 
 
0 2 4 6 8 10 12 14 16 18 20 22 24
0
10
20
30
40
50
60
70
80
90
100
%
 p
o
rp
h
y
ri
n
 t
ra
n
s
fe
rr
e
d
Time (hours)
 MLV acceptor with 3% PVA
 MLV acceptor without PVA
0 2 4 6 8 10 12 14 16 18 20 22 24
0
10
20
30
40
50
60
70
80
90
100
 
 
%
 p
o
rp
h
y
ri
n
 t
ra
n
s
fe
rr
e
d
Time (hours)
Figure 4.35: Porphyrin transfer (centrifugation method) from the resuspended crystalline lipid 
nanoparticles of FS75/SGChigh and the original crystalline lipid nanoparticles of Fpoloxamer/DCP 
to the acceptor o/w emulsion, molar ratio 1:25; measurement results (left), fitted curve (right), n = 3. 
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Table 4.11: Results of the transfer studies with porphyrin obtained by the centrifugation technique 
assuming transfer kinetics according to equation [1] 
 
4.4.2 Transfer of Nile red to MLV and emulsion droplets 
In order to determine the effect of lipophilicity on the transfer, Nile red, which is less 
lipophilic than porphyrin, was used as a drug model. The transfer of Nile red from the 
resuspended lipid nanoparticles of FS75/SGChigh in the liquid or crystalline form to the 
different acceptor particles was studied with a molar ratio of 1:100. The liquid nanoparticles 
were used with the acceptor MLV while the crystalline nanoparticles were used with the 
acceptor emulsion. In contrast to porphyrin transfer, the transfer of Nile red to the different 
acceptor particles was complete and equivalent to the expected equilibrium value. The 
transfer of Nile red seemed to be completed after about 2 minutes (figure 4.37, table 4.12). 
Large differences were thus observed between the transfer of porphyrin and Nile red. Firstly, 
the porphyrin transfer reached an equilibrium value much lower than the expected one at a 
molar ratio of 1:100 while the Nile red transfer reached the expected equilibrium value. 
Donor Acceptor Molar ratio 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time 
FS75/SGClow
 
 
(liquid) 
MLV 
1:25 0.0054  0.0003 36  1.9 12.4 h 
1:50 0.0066  0.0009 59  1.57 10.5 h 
1:100 0.0068  0.0016 64  1 10 h 
FS75/SGChigh 
(liquid)
 MLV 
1:25 0.005  0.0005 34.5  2.1 12.5 h 
1:50 0.0065  0.001 53  1.15 10.8 h 
1:100 0.0065  0.0007 61  1.7 10 h 
FS75 (liquid) MLV 
1:25 0.0055  0.0002 32   1.6 12.4 h 
1:50 0.0066  0.0003 52  0.9 10.5 h 
1:100 0.006  0.0011 59  1.5 11 h 
Fpoloxamer/DCP 
(liquid)
 MLV 
1:25 0.0055  0.0009 37  1 12.4 h 
1:50 0.0061  0.0008 57  1.57 11 h 
1:100 0.0068  0.0004 65  1.9 10 h 
Fpoloxamer/DCP 
(liquid) 
MLV (3% PVA) 1:100 0.006  0.0005 60  1.8 11 h 
FS75/SGChigh 
(crystalline)
 O/w emulsion 1:25 1.28  0.15 32  0.75 3 min 
Fpoloxamer/DCP 
(crysrtalline)
 O/w emulsion 1:25 1.38  0.25 33  1.9 3 min 
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The rate of porphyrin transfer was very low especially to the acceptor MLV and increased 
with the emulsion acceptor while the rate of Nile red transfer was nearly the same with the 
two acceptors (MLV and emulsion). As observed before for the porphyrin transfer, the 
transfer rate of Nile red to the acceptor MLV (1.9 min-1) was lower than that to the acceptor 
o/w emulsion (3.3 min-1). This might be due to the difference in the particle size of the two 
acceptors and thus the difference in the number of acceptor particles in the transfer mixture. 
The difference in the transfer between Nile red and porphyrin could be attributed to the 
difference in the lipophilicity between the two drug models. Nile red is less lipophilic than 
porphyrin, which allows the fast diffusion of Nile red molecules to the acceptor particles. Also 
this difference in the lipophilicity facilitates the rapid diffusion of Nile red from layer to layer 
within the MLV acceptor. 
 
Table 4.12: Results of the transfer studies with Nile red obtained by the centrifugation technique at a 
molar ratio of 1:100, assuming transfer kinetics according to equation [1] 
 
 
4.4.3 Transfer of different drug models to cubic monoolein particles 
In order to measure the drug transfer to large acceptor particles other than the acceptor 
MLV and emulsion, cubic monoolein particles were used as acceptor particles. The transfer 
of porphyrin from the crystalline particles of FS75/SGChigh was studied to acceptor 
monoolein cubic particles with different sizes to investigate the effect of particle size on the 
Donor Acceptor 
Transfer rate constant 
K (min
-1
) 
Final % 
transferred 
Equilibrium time 
(min) 
FS75/SGChigh  
MLV 1.9  0.08 98  1.8 2.5 
O/w emulsion 3.3  0.37 101  1.9 1 
Figure 4.37: Nile red transfer (centrifugation method) from the resuspended lipid nanoparticles of 
FS75/SGChigh to the acceptor o/w emulsion and the acceptor MLV, molar ratio 1:100, 
measurement results (left), fitted curve (right), n = 3. 
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transfer rate. The acceptor cubic particles, which were prepared from 5 and 10% amphiphile 
(12% poloxamer) by autoclaving, were used in the transfer experiment. Ultracentrifugation 
was a successful method for the separation between the acceptor cubic particles 
(supernatant creamy emulsion layer) and the donor crystalline nanoparticles (pellets) (figure 
4.38). Figure 4.38 gives a good illustration of the transfer of porphyrin from the crystalline 
particles to the acceptor cubic particles. As reflected in the pink color of the creamy acceptor 
layer and the white pellet layer, the drug was highly transferred to the acceptor cubic 
particles. The transfer was very rapid and after 1 minute about 94 and 90% had been 
transferred to the acceptor cubic particles with a particle size of 0.32 and 0.71 µm, 
respectively (figure 4.39). Equilibrium was obtained after about 1.5 minutes with both 
acceptors and the amount of porphyrin transferred at equilibrium was the same as the 
expected value. The transfer rate constant was 2.54 and 2.42 min-1 for the cubic particles 
with a particle size of 0.32 and 0.71 µm, respectively (table 4.13).  
By comparing the transfer of porphyrin to the acceptor MLV, emulsion and cubic 
particles, it was found that porphyrin had a high affinity to monoolein cubic particles.  
Figure 4.39: Porphyrin transfer (centrifugation method) from the crystalline donor particles of 
FS75/SGChigh to the acceptor cubic particles with different particle sizes, molar ratio 1:25, 
measurement results (left), fitted curve (right), n = 3. 
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Figure 4.38: Optical appearance of supernatant and pellet after ultracentrifugation of the mixture of 
FS75/SGChigh and the cubic particles at 55000 rpm for 30 minutes Ultracentrifugation was carried 
out after 5 minutes of mixing the donor and acceptor with a molar ratio of 1:25 
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Table 4.13: Results of the transfer studies with porphyrin and Di  obtained by the centrifugation 
technique assuming transfer kinetics according to equation [1] 
 
Although the transfer rate to the acceptor cubic particles was nearly the same as to 
the acceptor emulsion, the amount transferred to the cubic particles was higher than to the 
emulsion. Compared with the acceptor MLV, the rate and amount of porphyrin transferred to 
the acceptor cubic particles were higher than to the acceptor MLV. These differences 
between the three acceptors might be attributed to the unique structure of the cubic particles 
where the monoolein bilayer (internal structure) is extending in three dimensions, with a high 
specific bilayer/water interfacial area (500-600 m2/g lipid) [17]. This unique structure of the 
cubic particles facilitates the diffusion of porphyrin molecules within the bilayer. On the other 
hand, presence of cholesterol in the acceptor MLV increases the rigidity of the membrane 
surface and thus decreases the rate of porphyrin transfer to the internal bilayer. In addition, 
the cubic particles had a smaller particle size (0.32, 0.71 µm) than the emulsion (6 µm) and 
MLV (10 µm), which leads to a higher number of cubic particles in the transfer mixture. 
Due to the high affinity and transfer rate that was observed with porphyrin to the 
acceptor monoolein dispersion, further transfer experiments were carried out with the more 
lipophilic drug model Di  to the monoolein acceptor. In contrast to the transfer to the acceptor 
emulsion [6] and unilamellar vesicles (column method), most of Di  was transferred after  
40 minutes with donor:acceptor molar ratio of 1:100 (figures 4.40 and 4.41, table 4.13). The 
transfer experiments of Di  to the acceptor cubic particles with the ultracentrifugation method 
thus showed the same results as observed before with the column method. With both 
methods, the equilibrium amount was about 80% and 65% with molar ratios of 1:25 and 
1:100, respectively, and these equilibrium amounts were reached after about 45 minutes with 
the different transfer methods and the different lipid ratios. 
 
4.4.4 Practical considerations of the centrifugation method 
Although the transfer experiments with the centrifugation method do not require the use 
of columns this method is more tedious than the column method because it requires longer 
Donor Acceptor 
Molar 
ratio 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time (min) 
Fpoloxamer/DCP 
(porphyrin) 
Cubic particles 
(0.32 µm) 
1:25 2.54  0.35 97 1.5 
Cubic particles 
(0.71 µm) 
1:25 2.42  0.24 96.5 1.8 
FS75/SGChigh 
(Di ) 
Cubic particles 
(0.32 µm) 
1:25 0.093  0.006 69.8  1.4 42 
1:100 0.09  0.011 82.9  1.6 43 
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separation times between the donor and acceptor particles. For each time point in each 
transfer experiment, three samples (transfer mixture) should be diluted and centrifuged, 
which is very time consuming. Furthermore, after separation between the donor and acceptor 
particles, the pellets need to be scraped from the centrifugation tube and dissolved before 
measuring the drug concentrations. In the case of rapid transfer, each time point was 
performed as a separate experiment which makes the measurements of rapid transfer with 
this method very difficult. Moreover, the centrifugation time was 10 and 30 minutes with the 
acceptor MLV and emulsion or cubic particles, respectively, which means that the time 
resolution of the method is not below 10 minutes. Also during these long separation times the 
transfer can continue. In addition, one of the two populations (donor or acceptor) should be in 
a crystalline form and the other in a liquid form to be easily separated by centrifugation. 
 
Figure 4.40: Supernatant containing the creamy acceptor cubic particles with the characteristic Di  
color after ultracentrifugation at 45000 rpm for 30 minutes. Ultracentrifugation was carried out after 1 
hour of mixing the donor FS75/SGChigh and acceptor cubic particles with a molar ratio of 1:100. 
Figure 4.41: Di  transfer (centrifugation method) from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor autoclaved monoolein cubic particles prepared from 5% amphiphile 
(320 nm) with different molar ratios, measurement results (left), fitted curve (right), n = 3. 
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4.5 Transfer studies with the flow cytometric method 
Flow cytometry is mainly used for cell studies. It has also been used for the 
characterization and quantification of lipid particles like liposomes and emulsion droplets [59, 
61, 96-98]. Recently, it has been used to investigate drug transfer between lipid particles [6]. 
In order to obtain more precise results for the rate of drug transfer, it is useful to work with the 
flow cytometric method, which is characterized by a very good time resolution and can detect 
large acceptor particles, which have a particle size of more than 1 µm [59-61].  
 
4.5.1 Porphyrin transfer from trimyristin nanoparticles to MLV and emulsion 
Porphyrin transfer studies from Fpoloxamer/DCP to the acceptor emulsion and MLV 
were carried out using the flow cytometric method with different molar ratios between the 
donor and acceptor (1:25, 1:50 and 1:100). With regard to the particle size, the detection 
limits of the flow cytometer used in this investigation are between 0.5 and 40 µm [6]. The 
acceptor particles with mean particle sizes of about 10 µm and 6 µm for the MLV and 
emulsion, respectively, fit into this size interval. The lower size detection limit of 0.5 µm 
indicates that a detection of the donor particles with a z-average diameter below 0.2 µm will 
not be possible and thus that these small particles will not disturb the measurements. 
By comparing the drug transfer to the acceptor emulsion and MLV a large difference in 
the rate of drug transfer could be observed between the two types of acceptors (figures 4.42, 
4.43 and 4.44). Equilibrium was obtained after about 4 or 5 minutes in case of the acceptor 
emulsion with all investigated lipid ratios while in the case of the MLV acceptor the 
equilibrium was obtained after about 12 hours with the all lipid ratios. The amount of drug 
transferred at equilibrium with the two acceptors was quite similar with the comparable lipid 
ratios (table 4.14). In the case of the MLV acceptor, the amount transferred from the liquid 
form of Fpoloxamer/DCP was 32, 45 and 59% for a molar ratio of 1:25, 1:50 and 1:100, 
respectively, while in the case of the acceptor emulsion it was 32, 46 and 62% for the three 
molar ratios. These results indicate that the difference between the MLV and emulsion 
acceptor was mainly in the rate of drug transfer but the final amount transferred was nearly 
the same. These observations confirm the results that were obtained by the centrifugation 
method with the acceptor MLV and emulsion. Also the equilibrium values were the same as 
with the centrifugation method, which were less than the expected equilibrium values.  
With both acceptors and as expected, increasing the molar ratio from 1:25 to 1:50 and 
1:100 led to an increase in the amount of drug transferred to the different acceptors. This 
increase in the drug transfer by increasing the molar ratio was due to the increase in the 
number of the acceptor particles in the transfer mixture. As observed previously with the 
acceptor unilamellar vesicles using the ion exchange column method, a slightly higher drug 
transfer was obtained from the crystalline donor particles than from the liquid particles (figure 
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4.43). This difference in drug transfer was most pronounced with a molar ratio of 1:100 
between the donor and acceptor. 
Figure 4.43: Porphyrin transfer (flow cytometry) from the liquid and crystalline nanoparticles of 
Fpoloxamer/DCP to the acceptor emulsion with different molar ratios, measurement results (left), 
fitted curves (right), n = 3. 
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Figure 4.44: Porphyrin transfer (flow cytometry) from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor emulsion with different molar ratios, measurement results (left), fitted 
curves (right), n = 3. 
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Figure 4.42: Porphyrin transfer (flow cytometry) from the liquid nanoparticles of Fpoloxamer/DCP to 
the acceptor MLV with different molar ratios, measurement results (left), fitted curves (right), n = 3. 
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Table 4.14: Results of the transfer studies with porphyrin obtained by the flow cytometric technique 
assuming transfer kinetics according to equation [1] 
 
 
4.5.2 Porphyrin transfer from the Miglyol nanoemulsion to an o/w emulsion 
Assuming an equal porphyrin distribution between the donor and acceptor, about 99% 
of the porphyrin was expected in the different acceptors (MLV, unilamellar vesicles and 
emulsion) at a molar ratio of 1:100 between the donor and acceptor. The maximum amount 
of porphyrin transferred to the different acceptors was, however, less than this expected 
value. To find the reason for this difference between the expected and the actual amount of 
drug transferred and to study the effect of drug affinity on the transfer, the transfer 
experiment was carried out from Miglyol nanoparticles loaded with porphyrin (donor) to the 
acceptor o/w emulsion, which was prepared also from Miglyol. As observed before in the 
transfer from the different donor particles to the acceptor emulsion, the transfer was very 
rapid and equilibrium was reached after 4 minutes (figure 4.45) with a transfer rate constant 
(K) of 1.07 min-1. The equilibrium amount was about 68%, which was much less than the 
expected distribution equilibrium (99%) for the molar ratio of 1:100. According to these 
Donor Acceptor Molar ratio 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time 
Fpoloxamer/DCP 
(liquid) 
MLV 
1:25 0.0053  0.0002 32  1.7 12.8 h 
1:50 0.0058  0.0006 45  1.5 11.8 
1:100 0.006  0.0005 58.5  1.9 11.9 
Fpoloxamer/DCP 
(liquid) 
O/w 
emulsion 
1:25 0.9  0.04 32.5  1.5 4.2 min 
1:50 0.8  0.07 46.5  1.2 5 min 
1:100 0.9  0.08 62   1.6 4.9 min 
Fpoloxamer/DCP 
(crystalline) 
O/w 
emulsion 
1:25 0.913   0.06 33.5  0.9 4.5 min 
1:50 0.8  0.08  49  1.9 5 min 
1:100 0.85   0.06 67   1.6 5.2 min 
FS75/SGChigh 
(crystalline)
 
O/w 
emulsion 
1:25 0.95  0.03 33  1.1 4.4 min 
1:50 0.85  0.04 47  0.9 5.4 min 
1:100 0.8  0.07 65  1.5 5.5 min 
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results, the affinity to the matrix lipid was not the reason for the difference between the 
expected distribution value and the actual value because in this experiment the transfer was 
carried out by using acceptor and donor prepared from the same lipid (Miglyol oil) but still the 
equilibrium values were less than the expected one.  
 
4.5.3 Transfer of porphyrin from tristearin nanoparticles to an o/w emulsion 
The transfer of porphyrin from tristearin lipid nanoparticles in the different polymorphic 
forms (  and  form) to the acceptor o/w emulsion was studied using the flow cytometric 
technique with a molar ratio of 1:100. The rate of drug transfer (about 1 min-1) observed with 
the tristearin (D118) nanoparticles was nearly the same as observed before with trimyristin 
(D114) (figure 4.46, table 4.15).  
Figure 4.45: Porphyrin transfer (flow cytometry) from Miglyol nanoparticles prepared with 4% 
poloxamer to the acceptor o/w emulsion with a molar ratio of 1:100, measurement results (left), 
fitted curve (right), n = 3. 
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Figure 4.46: Porphyrin transfer (flow cytometry) from the tristearin (D118) nanoparticles stored at 
4°C ( -polymorph) or at 23°C after heating to 50°C for 8 hours ( -polymorph) to the acceptor 
emulsion with a molar ratio of 1:100, measurement results (left), fitted curve (right), n = 3. 
 
0 2 4 6 8 10 12 14 16 18 20
0
10
20
30
40
50
60
90
100
D118, 4% PVA
D118, 1.8% S75-3, 0.45% SGC
%
 p
o
rp
h
y
ri
n
 t
ra
n
s
fe
rr
e
d
Time (minutes)
 -polymorph
 -polymorph
0 2 4 6 8 10 12 14 16 18 20
0
10
20
30
40
50
60
90
100
 
   
%
 p
o
rp
h
y
ri
n
 t
ra
n
s
fe
rr
e
d
Time (minutes)
Chapter 4: Results and discussion 
 
  80 
Table 4.15: Results of transfer studies of porphyrin from the D118 lipid nanoparticles to the acceptor 
o/w emulsion with a molar ratio of 1:100 obtained by the flow cytometric technique assuming transfer 
kinetics according to equation [1] 
 
a 
stored at 4°C 
b 
stored at 23°C after shaking at 50°C for 8 hours 
 
There was no difference in the course of porphyrin transfer between the nanoparticles in the 
two different polymorphic forms. For D118 nanoparticles stabilized with different stabilizers, 
equilibrium was obtained after a few minutes with an equilibrium amount transferred of about 
45% and 58% for D118 particles stabilized with 1.8% S75-3/0.45% SGC and 4% PVA, 
respectively (figure 4.46, table 4.15). The rate of drug transfer was nearly the same in the 
differently stabilized dispersions but the equilibrium amount in case of S75-3/SGC stabilized 
nanoparticles was much lower than for the PVA stabilized nanoparticles. This low equilibrium 
amount might be due to the formation of a rigid phospholipid shell by the stabilizer S75-3 
surrounding the triglyceride core of the nanoparticles [65-66].  
 
4.5.4 Porphyrin and Di  transfer to the acceptor cubic particles 
Complete porphyrin transfer within few minutes was observed with the acceptor cubic 
particles using the centrifugation and the ion exchange column methods. In order to obtain 
more precise results in the amount and rate of drug transfer, it is useful to work with the flow 
cytometric method. As observed before with the other methods (centrifugation and column 
method) porphyrin transfer to the acceptor cubic particles detected by flow cytometry was 
very rapid and completed within 3 minutes (figure 4.47, table 4.16). The transfer rate 
constant was 1.6 and 1.5 min-1 and the final percentage of drug transferred was 98 and 
97.5% for the cubic particles with the particle size of 1.2 and 2.1 µm, respectively. These 
results obtained from flow cytometry confirm the results that were obtained with 
centrifugation and the column method. They indicate that porphyrin transfer to the different 
acceptor cubic particles was very rapid and complete (the drug transfer at equilibrium was 
about the same as the expected value). By comparing these results of porphyrin transfer to 
the acceptor cubic particles with the results of porphyrin transfer to the other acceptors 
Donor 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time (minutes) 
5% D118, 4% PVA ( -form) 
a 
1.1  0.087 57% 3.5 
5% D118, 4% PVA ( -form) 
b 
1.1  0.09 58% 3.8 
5% D118, 1.8% S75-3, 0.45% SGC ( -form) 
a 
1.1  0.06 45% 4 
5% D118, 1.8% S75-3, 0.45% SGC ( -form) 
b 
1  0.07 46% 4.1 
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(emulsion, MLV and unilamellar vesicles) with the different transfer methods, it could be 
observed that complete porphyrin transfer was only observed with the acceptor cubic 
particles, while in the case of the other acceptors porphyrin transfer at equilibrium was not 
the same as the expected value. As mentioned before, the cubic phase is characterized by 
an extremely high membrane area to which the drug can be transferred and this explains the 
complete porphyrin transfer that was observed with the acceptor cubic particles in 
comparison with the other acceptors. By comparing the transfer rate constant of porphyrin to 
the acceptor monoolein dispersions using the three different techniques (ion exchange 
column, centrifugation and flow cytometry) it could be observed that the transfer rate 
constant of porphyrin using the flow cytometric technique (about 1.5 min-1) was lower than 
the transfer rate constant derived from the centrifugation and ion exchange techniques 
(about 2.5 min-1). This difference can be attributed to the difference in the time resolution. 
Column and centrifugation technique require the separation of the donor and acceptor 
particles and during the time required for separation the transfer can continue. Thus, column 
and centrifugation technique lead to an overestimation of the transfer rate constant. The best 
technique to measure the rapid porphyrin transfer to the cubic particles was the flow 
cytometric one, which has a very good time resolution and does not require the critical step 
separating the donor and acceptor.  
The results of Di  transfer using the flow cytometric technique confirmed the results that 
were obtained from the centrifugation and column technique (figure 4.48, table 4.16). For the 
transfer of Di , there were no differences between the three techniques (ion exchange 
column, centrifugation and flow cytometry). This can be explained by the moderate transfer 
rate of Di  for which the time resolution is not a critical factor.  
 
 
 
Figure 4.47: Porphyrin transfer (flow cytometry) from the crystalline donor particles of 
Fpoloxamer/DCP to the acceptor cubic particles with different particle sizes at a molar ratio of 1:25, 
measurement results (left), fitted curve (right), n = 3. 
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Table 4.16: Results of the transfer studies with porphyrin and Di  obtained by the flow cytometric 
technique assuming transfer kinetics according to equation [1] 
 
4.5.5 Porphyrin transfer from the donor monoolein dispersions to an o/w emulsion 
The transfer experiments from the monoolein/poloxamer dispersions (vesicles and 
cubic particles) to the acceptor emulsion with the flow cytometric method were carried out to 
confirm the affinity of porphyrin to the monoolein dispersions. At a donor:acceptor ratio of 
1:100, the rate of drug transfer was low (about 0.7 h-1) and the final percent transferred was 
about 50% with both types of donor particles (figure 4.49, table 4.17). Equilibrium was 
obtained after about 6 hours. In contrast, the transfer from D114 donor lipid nanoparticles to 
the same acceptor emulsion equilibrated after about 3 minutes. The transfer from the donor 
monoolein dispersion was thus very slow in comparison with the donor D114 lipid 
nanoparticles. By using these monoolein dispersions as acceptor particles, rapid and almost 
complete drug transfer was observed and by using them as donor particles, the drug transfer 
was very low. The results of the monoolein dispersions as acceptor particles in one 
experiment and as donor in the other experiments indicate the high affinity of porphyrin to 
monoolein dispersions.  
Donor Acceptor 
Molar 
ratio 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time (min) 
Fpoloxamer/DCP 
(porphyrin) 
 
Cubic particles  
(1.2 µm) 
1:25 1.6  0.21 98  1.8 2.8 
Cubic particles  
(2.1 µm) 
1:25 1.5  0.15 97.5  2.4 3 
FS75/SGChigh 
(Di )  
 
Cubic particles  
(2.1 µm) 
1:25 0.105  0.003 64  1.5 40 
1:100 0.1  0.004 82  1.7 40 
Figure 4.48: Di  transfer (flow cytometry) from the resuspended crystalline nanoparticles of 
FS75/SGChigh to the acceptor monoolein cubic particles prepared from 15% amphiphile (particle 
size 2.1 µm) with different molar ratios, measurement results (left), fitted curve (right), n = 3. 
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Table 4.17: Results of the transfer studies with porphyrin from the monoolein dispersions to the 
acceptor emulsion droplets at a molar ratio of 1:100 obtained by the flow cytometric technique 
assuming transfer kinetics according to equation [1] 
 
 
4.5.6 Nile red transfer to the acceptor MLV and o/w emulsion  
The transfer of Nile red, which is a less lipophilic dye than porphyrin, was very rapid 
and equilibrated after few minutes as observed by the column and centrifugation method. In 
order to calculate the transfer rate constant and also to obtain results from a method that has 
an even better time resolution, experiments were performed with the flow cytometric method. 
The transfer results of Nile red to the acceptor emulsion and MLV are illustrated in figure 
4.50. The transfer of Nile red seemed to be completed after about 3 minutes with the different 
acceptors (as observed in the transfer experiments with the centrifugation and column 
method). After 15 seconds, the percentage of drug transferred was 53 and 47% for the 
acceptor emulsion and MLV, respectively, and after 1 minute more than 75% of the drug had 
been transferred with both formulations. The amount of Nile red transferred at equilibrium 
was the same as the expected value, which indicates that all of the Nile red must have 
transferred from the donor particles to the different acceptors. The transfer rate constant was 
1.9 and 1.05 min-1 for the acceptor emulsion and MLV, respectively (table 4.18).  When 
comparing the transfer rate constant of Nile red to the acceptor MLV and emulsion obtained 
Donor Transfer rate constant K (min
-1
) 
Final % 
transferred 
Equilibrium time 
(h) 
Monoolein vesicles 0.012  0.008 54  0.5 5.7 
Monoolein cubic particles 0.011  0.005 52  0.3 6 
Figure 4.49: Porphyrin transfer (flow cytometry) from the donor monoolein/poloxamer dispersions 
(vesicles or cubic particles) to the acceptor Miglyol emulsion with a molar ratio of 1:100, 
measurement results (left), fitted curve (right), n = 3. 
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by the centrifugation and flow cytometric technique (table 4.18), it is obvious that the transfer 
rate constant to both acceptors derived from the centrifugation technique was higher than the 
transfer rate constant obtained from the flow cytometric technique. As discussed before, this 
difference in the transfer rate constant can be attributed to the rapid drug transfer of Nile red 
and the long separation time between the donor and the acceptor resulting in an 
overestimation of the transfer rate constant by the centrifugation method. 
 
4.5.7 Practical considerations of the flow cytometric method 
Since the flow cytometric method does not require a separation between the donor and 
acceptor particles, it is considered as the easiest method compared to the other methods 
(column and centrifugation method). Although this advantage of the flow cytometric 
technique it requires the use of fluorescent substances as drug model and large acceptor 
particles which can be recognized by a flow cytometer. This means that the transfer to the 
acceptor unilamellar vesicles and monoolein vesicles cannot be measured using this 
technique. 
 
Table 4.18: Results of the transfer studies from the resuspended nanoparticles of FS75/SGChigh with 
Nile red at a molar ratio of 1:100 assuming transfer kinetics according to equation [1] 
 
 
 
Transfer method Acceptor 
Transfer rate 
constant K (min
-1
) 
Final % 
transferred 
Equilibrium 
time (min) 
Flow cytometry 
MLV 1.05  0.07 100.5  1.5 4 
O/W emulsion 1.9  0.05 100  1.15 2.5 
Centrifugation 
MLV 1.9  0.08 98  1.8 2.5 
O/W emulsion 3.3  0.37 101  1.9 1  
Figure 4.50: Nile red transfer (flow cytometry) from the resuspended crystalline lipid nanoparticles 
of FS75/SGChigh to different acceptor particles with a molar ratio of 1:100, measurement results 
(left), fitted curve (right), n = 3. 
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Chapter 5: Final discussion  
 
The aim of this study was to measure the transfer of different drug models from lipid 
nanoparticles to different lipophilic acceptors and to determine the factors affecting this 
transfer. Transfer measurements to different lipophilic acceptor compartments were used 
instead of measuring the drug release into the aqueous phase to better mimic the 
environment encountered by the drug in the body. In addition to these transfer 
measurements, a comparison between three different techniques, which were used to 
measure the transfer, was an important goal of this study. Lipid nanoparticles were chosen 
as donor particles due to their advantages, which include their small particle size, 
toxicological safety and the possibility of large-scale production. Lipid nanoparticles from 
trimyristin were prepared by using different concentrations of S75, SGC and poloxamer as 
stabilizers. To eliminate a potential influence of additional colloidal structures, the lipid 
nanoparticles were separated from the excess liposomes, which were formed during 
homogenization. Ultracentrifugation was a good technique to separate the lipid nanoparticles 
from the liposomes but a small amount of the lipid nanoparticles was lost due to the 
centrifugation procedure. Trimyristin nanoparticles can exist in two different physical states, 
depending on storage conditions after preparation by melt-homogenization. After cooling to 
room temperature, the nanoparticles are present in the form of emulsion droplets whereas 
storage at lower temperatures, e.g. in a refrigerator, will lead to crystallization of the matrix 
lipid. 
Many factors affecting the drug transfer from the lipid nanoparticles were studied such as the 
physical state of the nanoparticles, particle size of the acceptors, molar ratio between the 
donor and acceptor, the type of the acceptor lipid, the total lipid concentration in the transfer 
mixture and the lipophilicity of the drug model. During the crystallization of the nanoparticles, 
expulsion of the drug to the surface of the nanoparticles took place, which made the transfer 
from the crystalline nanoparticles slightly higher than the liquid one [6]. Increasing the 
acceptor to donor ratio led to an increase in the available surface area of the acceptor and 
thus increased the amount of drug transferred. On the other hand, increasing the total lipid 
concentration in the transfer mixture led to a decrease in the distance between the donor and 
acceptor particles in the transfer mixture which in turn increased the transfer rate of the drug. 
The effect of the type of the lipid that was used in the preparation of the acceptor particles 
was demonstrated by comparing the transfer of porphyrin to the acceptor monoolein vesicles 
and the unilamellar vesicles, which were prepared from EPC and cholesterol. Although both 
are vesicles and nearly have the same size the transfer to the acceptor monoolein vesicles 
was faster than to the vesicles, which were prepared from EPC and cholesterol. In addition to 
this faster transfer, the transfer to the acceptor monoolein vesicles was complete while the 
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transfer to the acceptor EPC vesicles was incomplete. Monoolein is more hydrophobic than 
EPC, which may explain the high affinity of the lipophilic porphyrin to the acceptor monoolein 
vesicles. In addition, the acceptor EPC vesicles contain cholesterol, which increases the 
rigidity of the vesicles bilayer and thus may decrease the rate of porphyrin transfer to the 
acceptor EPC vesicles. The transfer of porphyrin to the acceptor emulsion was very rapid 
with a transfer rate constant nearly the same as for the acceptor monoolein dispersions. 
Similar results were previously reported for the transfer of porphyrin from trimyristin lipid 
nanoparticles to the acceptor emulsion [6]. Although the acceptor MLV had the same 
composition as the acceptor unilamellar vesicles the transfer of porphyrin to the acceptor 
MLV was slower than to the acceptor unilamellar vesicles, which might be attributed to the 
differences in the particle size and lamellarity of the two acceptors. The large particles size of 
the acceptor MLV decreased the number of the acceptor particles in transfer mixture as 
compared with the acceptor unilamellar vesicles which had a small particle size and thus a 
higher number of acceptor particles in the transfer mixture.    
The lipophilicity of the drug model was another factor, which affected the drug transfer and 
this factor was studied by measuring the transfer of different drug models with different 
degrees of lipophilicity. The transfer of Nile red, which is the least lipophilic drug model, was 
very rapid and complete to the different acceptors due to its rapid diffusion to the acceptor 
particles and also the rapid diffusion from layer to layer within the acceptor particles (MLV). 
The transfer of porphyrin, which is more lipophilic than Nile red, occurred at the lipid water 
interface [6, 84]. By increasing the lipid water interface as in case of the acceptor cubic 
particles, complete and very rapid drug transfer was observed. In contrast to the acceptor 
cubic particles, porphyrin transfer to the other acceptors (MLV, emulsion and unilamellar 
vesicles) was incomplete which confirmed the fact that porphyrin transfer was limited to the 
lipid water interface and saturation of this interface led to termination of the transfer at values 
less than the expected values. Furthermore, porphyrin appears to have a higher affinity to 
apolar lipids than Nile red which explains the less pronounced transfer from the donor lipid 
nanoparticles as compared with Nile red [99]. This high affinity to apolar lipids explains also 
the high transfer rate and amount of porphyrin to the acceptor monoolein dispersions 
because monoolein is more lipophilic than the other acceptor lipids. The transfer of Di , which 
is the drug model with the highest lipophilicity, was very slow and the transfer stopped at very 
low values except with the acceptor monoolein dispersions. 
The transfer rate is a very important parameter in the transfer experiments. In some transfer 
experiments, the transfer was very rapid and the equilibrium was obtained after few minutes. 
The centrifugation and the ion exchange column technique were not suitable to measure this 
very rapid transfer in an undistorted way because in both techniques a separation between 
the donor and acceptor was required. This separation took time and during this time the 
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transfer can continue which led to an overestimation of the transfer rate constant. This is 
considered as the most important disadvantage of both methods, which was overcome with 
the flow cytometric technique. The flow cytometry was the best technique to measure these 
very rapid transfer rates because it does not need the separation step between the donor 
and acceptor. Thus the transfer rate that was obtained from the flow cytometric technique 
was more precise than the transfer rate constant that was obtained from the centrifugation 
and column technique for rapid drug transfer. In addition to the inaccurate transfer rate 
constant that was calculated from the centrifugation and ion exchange column technique, 
other disadvantages were observed with both techniques. In case of the centrifugation 
technique one of the two populations (donor or acceptor) should be in the liquid state while 
the other should be in the crystalline form to be easily separated from each other. The 
acceptor MLV particles are neither crystalline nor liquid but they were prepared with a highly 
concentrated sucrose solution in order to be easily separated as pellet after centrifugation. 
With the ion exchange column technique one of the two populations should be charged and 
the other should be neutral and both populations should be of small particle size to avoid 
blockage of the column. These requirements were not needed in the flow cytometric 
technique but the flow cytometric technique depends on the use of fluorescent substances as 
drug model and large acceptor particles which can be recognized by a flow cytometer. This 
means that the transfer to the acceptor unilamellar vesicles and monoolein vesicles cannot 
be measured using this technique. Concerning the performance of the three techniques, the 
centrifugation technique is a tedious technique because it needs a long time to separate the 
donor and acceptor particles and after this separation the pellets and the supernatant should 
be dissolved to measure the drug concentration. In contrast, the flow cytometry is the easiest 
technique because it does not need the separation between the donor and acceptor 
particles, which allows the direct measurement of the transfer mixture. 
Many conclusions can be derived from this study, first each technique has its own 
advantages and disadvantages and the choice of the technique that can be used to measure 
the transfer depends on several factors such as the physicochemical properties of both 
populations (donor and acceptor particles) and the type of the drug. Second, compared to 
commonly applied release methods, the transfer to the different lipophilic acceptor 
compartments is better than the commonly applied release methods relative to the conditions 
in the blood. Finally, monoolein dispersions containing cubic particles or vesicles can very 
successfully be used as a new lipophilic acceptor compartment to measure the drug transfer 
from lipid nanoparticles. In addition to providing a good affinity for the lipophilic drug models 
under investigation the properties of the monoolein particles can be adapted to be used in all 
three transfer study techniques. 
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Chapter 6: Summary 
  
Many methods have been described to investigate the in vitro drug release of lipid 
nanoparticles, which appear to be of limited suitability due to the use of aqueous release 
media. In this study, in order to better mimic the environment encountered by the drug after 
administration, many lipophilic compartments were used to which the transfer of different 
drug models was measured. The detection of the substances transferred from lipid 
nanoparticles into the different lipophilic compartments was performed using the three 
different techniques centrifugation, ion exchange and flow cytometry. 
Different lipid donor nanoparticles were prepared using trimyristin and medium chain 
triglycerides as matrix lipids. Ultracentrifugation was carried out on the trimyristin 
nanoparticles to separate the nanoparticles from the excess phospholipid used as emulsifier. 
The nanoparticles were loaded with the three different drug models porphyrin, Nile red and 
Di . Differential scanning calorimetry (DSC), 31P NMR spectroscopy, cryo transmission 
electron microscopy (cryo-TEM) and high performance liquid chromatography of the donor 
lipid nanoparticles showed that the ultracentrifugation process did not only lead to the 
separation between the lipid nanoparticles and the excess S75 emulsifier but also to the loss 
of a small amount of the nanoparticles. The mean particle size of the different donor particles 
was less than 150 nm.  
Different lipophilic acceptor compartments were used in this study. Egg phosphatidyl choline 
and cholesterol were chosen for the preparation of acceptor multilamellar and unilamellar 
vesicles since they represent an unsaturated and uncharged bilayer that is similar to many 
physiological membranes. O/w emulsion droplets, which were prepared from Miglyol 812, 
were also used as acceptor particles. Monoolein dispersions (in the form of lyotropic liquid 
crystalline cubic particles or vesicles) were introduced as a new lipophilic acceptor 
compartment for drug transfer studies. Six monoolein dispersions were prepared with 
different concentrations of monoolein and poloxamer in order to obtain large cubic particles 
to be suitable for the use with the flow cytometric transfer technique. Monoolein dispersions 
were also applicable as acceptor particles for the transfer experiments with the other two 
techniques. 
A large difference was observed in the transfer of porphyrin to the different acceptors where 
the transfer was moderate to the acceptor MLV and rapid to the acceptor unilamellar 
vesicles. With monoolein dispersions and emulsions as acceptor, the transfer was very rapid 
and equilibrium was obtained after a few minutes. In case of the acceptor MLV, unilamellar 
vesicles and emulsion the transfer was not complete and the transfer stopped at 
concentrations lower than the expected values. This may be due to the saturation of the 
surface of the acceptor particles. In contrast, the transfer to the acceptor monoolein 
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dispersions was complete which means that the equilibrium values were the same as the 
expected values. The porphyrin transfer from the crystalline nanoparticles was slightly higher 
than from the liquid nanoparticles especially at a high acceptor/donor ratio.  
The transfer of Nile red, which is less lipophilic than porphyrin, was very rapid to all different 
acceptors employed (MLV, unilamellar vesicles and emulsion) with an equilibrium amount 
transferred that was nearly the same as the expected values. This was attributed to the 
ability of Nile red to diffuse and distribute within the acceptor particles. The transfer of Di , 
which is more lipophilic than porphyrin, to the acceptor monoolein cubic particles was slower 
than that of porphyrin and incomplete. Also the transfer rate and amount of Di  to the 
acceptor unilamellar vesicles was very low. The transferred amount of the different drug 
models highly depended on the acceptor to donor ratio and by increasing this ratio the 
amount of transferred drug increased. 
The transfer rate constant of porphyrin to the acceptor monoolein dispersions and emulsion 
derived from the centrifugation and ion exchange column technique was higher than the 
transfer rate constant obtained from the flow cytometric technique. This can be attributed to 
the rapid transfer of porphyrin to these acceptors and the inability of the two techniques 
(centrifugation and ion exchange column) to accurately measure the rapid transfer because 
they require the separation between the donor and acceptor particles and during this 
separation time the transfer can continue. The flow cytometric technique does not require this 
separation and thus it gives more accurate transfer rate constant than the other two 
techniques. The same was observed with the transfer of Nile red to the different acceptors 
because the transfer of Nile red was very rapid. Since the transfer of Di  was slower than the 
transfer of porphyrin to the acceptor monoolein dispersions and o/w emulsion and also 
slower than the transfer of Nile red to the different acceptors, the three techniques showed 
the same transfer results (transfer rate and amounts) of Di  to the acceptor cubic particles. In 
conclusion, this study shows that the transfer depends on several factors such as the 
physical state of the nanoparticles, particle size of the acceptors, molar ratio between the 
donor and acceptor, the type of the lipid that is used in the preparation of the acceptors, the 
total lipid concentration in the transfer mixture and the lipophilicity of the drug model. All three 
techniques studied are suitable to investigate the transfer of Di  while the flow cytometric 
technique is the best one to measure the very rapid transfer of porphyrin and Nile red. 
Finally, monoolein dispersions in the form of cubic particles or vesicles are very useful as 
acceptor particles for transfer studies with lipophilic drugs. 
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Zusammenfassung 
  
Es sind viele Methoden beschrieben, um die in vitro-Freisetzung aus Lipidnanopartikeln zu 
untersuchen. Allerdings sind diese aufgrund der Verwendung von wässrigen 
Freisetzungsmedien nur bedingt in dieser Arbeit geeignet. Um eine bessere Annäherung an 
in vivo-Zustände zu erreichen, wurden viele lipophile Kompartimente verwendet, in die hinein 
der Transfer verschiedener Arzneistoffmodelle gemessen wurde. Durch die drei 
unterschiedlichen Methoden Zentrifugation, Ionenaustausch und Durchflusszytometrie wurde 
der Transfer der unterschiedlichen Substanzen aus Lipidnanopartikeln in die verschiedenen 
lipophilen Kompartimente detektiert.  
Verschiedene Donor-Lipidnanopartikel wurden unter Verwendung von Trimyristin und 
mittelkettigen Triglyceriden als Matrixmaterialien hergestellt. Trimyristin-Nanopartikel wurden 
ultrazentrifugiert, um die Nanopartikel vom Überschuss der als Emulgator eingesetzten 
Phospholipide zu trennen. Die Nanopartikel wurden mit drei verschiedenen 
Arzneistoffmodellen beladen, Porphyrin, Nilrot und DiI. Differentialthermoanalyse (DSC), 31P-
NMR-Spektroskopie und Kryotransmissionselektronenmikroskopie (Kryo-TEM) sowie 
Hochleistungs-Flüssigchromatographie an den Donorpartikeln zeigten, dass die 
Ultrazentrifugation der Lipidnanopartikel nicht nur zur Trennung der Lipidnanopartikel vom 
Überschuss des S75-Emulgators führte, sondern auch den Verlust einer kleinen Menge der 
Nanopartikel verursachte. Die mittlere Teilchengröße der verschiedenen Donorpartikel betrug 
weniger als 150 nm. In dieser Studie wurden unterschiedliche lipophile Akzeptor-
Kompartimente verwendet. Zur Herstellung des MLV-Akzeptors und der unilamellaren 
Akzeptor-Vesikel wurden Ei-Phosphatidylcholin und Cholesterol eingesetzt, da sie eine 
ungesättigte und ungeladene Doppelschicht bilden, die vielen physiologischen Membranen 
ähnlich ist. Als Akzeptorpatikel sind ebenfalls o/w Emulsionspartikel aus Miglyol angewendet 
worden. Monoolein-Dispersionen (in Form von lyotrop-kubischen flüssigkristallinen Partikeln 
oder Vesikeln) wurden als neue lipophile Akzeptorkompartimente eingeführt. Sechs 
Monoolein-Dispersionen mit verschiedenen Konzentrationen von Monoolein und Poloxamer 
wurden hergestellt, um große kubische Partikel zu erhalten, die für die 
durchflusszytometrische Transfer-Technik geeignet sind. Für die beiden anderen 
Transfermethoden waren Monoolein-Dispersionen als Akzeptoren ebenfalls geeignet. 
Es wurden große Unterschiede im Transferverhalten von Porphyrin zu den verschiedenen 
Akzeptoren beobachtet. Die Übertragung auf den MLV-Akzeptor war mäßig, die auf die 
unilamellaren Akzeptor-Vesikeln hingegen schnell. Mit Monoolein-Dispersionen und 
Emulsionen als Akzeptor war der Transfer sehr schnell, und das Gleichgewicht war nach 
wenigen Minuten erreicht. Im Falle der MLV, unilamellaren Vesikel und Emulsion als 
Akzeptor kam der Transfer bei Konzentrationen unterhalb der erwarteten Werte zum 
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Stillstand, was wahrscheinlich auf die Sättigung der Partikeloberfläche des Akzeptors 
zurückzuführen ist. Im Gegensatz dazu war der Transfer zu den Akzeptorpartikeln aus 
Monoolein vollständig, d. h. die erwarteten Gleichgewichtswerte wurden erreicht. Der 
Porphyrin-Transfer aus den kristallinen Nanopartikeln war höher als der aus flüssigen 
Nanopartikeln, vor allem bei einem hohen Akzeptor / Donor-Verhältnis. Der Transfer von 
Nilrot, das weniger lipophil ist als Porphyrin, zu allen untersuchten Akzeptoren (MLV, 
unilamellare Vesikel und Emulsion) war sehr schnell. Die im Gleichgewicht übertragene 
Menge stimmte mit den erwarteten Werten fast überein. Dies könnte auf die Fähigkeit des 
Nilrots, sich in den Akzeptor-Teilchen zu verteilen, zurückzuführen sein. Es wurde eine 
geringe Übertragung des DiI zu den unilamelaren Akzeptor-Vesikeln beobachtet. Die 
transferierte Menge der verschiedenen Wirkstoffmodelle war stark abhängig vom Akzeptor-
zu-Donor-Verhältnis. Durch eine Erhöhung dieses Verhältnisses wurde die Menge des 
übertragenen Wirkstoffs erhöht. Die Geschwindigkeitskonstanten des Porphyrin-Transfers 
auf die Akzeptoren aus Monoolein und die Emulsionspartikel, die mit der Zentrifugations und 
Ionenaustauschmethode erhalten wurden, waren höher als die Geschwindigkeitskonstanten 
aus der Durchflusszytometrie. Dies kann auf die sehr schnelle Übertragung des Porphyrins 
zu diesen Akzeptoren zurückgeführt werden. Die beiden Methoden Zentrifugation und 
Ionenaustauschersäule sind nicht in der Lage, den raschen Transfer genau zu messen, weil 
sie auf einer Trennung zwischen den Donor- und Akzeptorteilchen beruhen und während des 
Trennungsvorgangs der Transfer fortgesetzt werden kann. Die Durchflusszytometrie benötigt 
keine Trennung, wodurch genauere Transferkonstanten erhalten werden können. Die 
gleichen Beobachtungen wurden für den Transfer des Nilrots zu den verschiedenen 
Akzeptoren, der ebenfalls sehr schnell war, gemacht. Da  der Transfer von DiI zu den 
Monoolein-Dispersionen und O/W-Emulsionen langsamer war als der des Porphyrins und 
ebenso langsamer war als der Transfer vom Nilrot zu den verschiedenen Akzeptoren, 
ergaben die drei Detektionsmethoden die gleichen Ergebnisse für den Transfer von DiI zu 
den Akzeptoren aus kubischen Teilchen. In dieser Arbeit konnte gezeigt werden, dass der 
Wirkstofftransfer von verschiedenen Faktoren abhängt, wie dem Aggregatzustand der Donor-
Nanopartikel, der Partikelgröße der Akzeptoren, dem Mengenverhältnis zwischen Donor und 
Akzeptor, der Art des Lipids, das für die Herstellung der Akzeptoren verwendet wurde, der 
Lipidgesamtkonzentration in der  Untersuchungsmischung und der Lipophilie des 
Modellwirkstoffs. Alle drei in dieser Studie eingesetzten Transfermethoden sind für die 
Untersuchung des DiI-Transfers geeignet, während die Durchflusszytometrie die beste 
Methode zur Messung des schnellen Transfers von Porphyrin und Nilrot ist. Schließlich 
können Monoolein-Dispersionen in Form von kubischen Teilchen oder Vesikeln vorteilhaft als 
Akzeptor-Partikel für Transferuntersuchungen mit lipophilen Wirkstoffen eingesetzt werden. 
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A.1 Calibration curves of the different drug models in the different solvents 
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Figure A.1: Calibration curves of the different drug models in the different solvents 
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A.2 Calibration curves of the different drug models using flow cytometer 
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Figure A.2: Calibration curves of the different drug models using flow cytometer 
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